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 i 
Abstract and Keywords 
There is evidence that defunctioning loop ileostomies (DLIs) are associated with decreased risk 
of clinically significant anastomotic leaks, but at what cost? This population-based retrospective 
cohort study used administrative data to investigate differences in outcomes between patients 
undergoing low anterior resection with and without DLIs.  We included all adult patients 
undergoing low anterior resection from 2002 to 2014 and identified outcomes within 30-days to 
2-year of the index surgery.  Outcomes included hospital readmission, reoperation, major 
complications, mortality, bleeding, and ileostomy reversal. DLIs were associated with 
significantly worse outcomes after low anterior resection, including increased risk of major 
complication, acute kidney injury, readmission, ventral hernia, bowel obstruction.  There is 
certainly a role for DLIs to decrease risk of significant anastomotic leak requiring intervention 
and/or operation; however, DLIs are not benign entities. Based on the results of this study, it can 
be argued that selective utilization of DLIs should be recommended and further research into risk 
stratification and identification of patients who would benefit the most from DLIs are warranted. 
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Chapter I: Introduction 
 
1.1 A review of current literature 
 
The most serious risk of a colorectal anastomosis is an anastomotic leak (AL). Clinical correlates 
of ALs include local or systemic sepsis, percutaneous intervention, reoperation, increased 
hospital length of stay, and increased risk of mortality. Defunctioning loop ileostomy (DLI) was 
introduced as a method to mitigate the clinical sequelae of AL [1]. A number of studies have 
shown that although DLI does not decrease the incidence of AL, it does decrease the severity of 
complications associated with ALs [2-5]. However, DLIs are not without risk and controversy 
still exists on when they should be utilized. The purpose of this review is to objectively examine 
the benefits and risks of defunctioning loop ileostomies based on a comprehensive review of 
current literature. 
 
1.2 Indications for defunctioning loop ileostomy 
 
Defunctioning loop ileostomies are most commonly fashioned after colorectal anastomosis for 
rectal cancer. Studies evaluating risk factors for ALs have shown that a low or ultra-low 
colorectal anastomosis is associated with significantly higher risk for leaks [5-7]. Other risk 
factors include male sex, age > 70 years, malnutrition, smoking, corticosteroid use, diabetes, and 
pre-operative radiation therapy [3,7,8,9]. As surgical techniques progressed throughout the years, 
the introduction of stapling devices allowed surgeons to fashion much lower colorectal 
anastomoses in hopes of preserving bowel continuity. Thus, there was an initial increase in ALs 
after low anterior resection (LAR) [10]. DLIs were introduced as a mechanism to divert the fecal 
stream from the newly formed anastomosis. The function is two-fold: first, if an AL occurs, the 
 2 
DLI will decrease septic complications from the leak by significantly decreasing fecal leakage 
and contamination; second, by diverting the fecal stream, there is less mechanical irritation on 
the new anastomosis [10]. 
 
Rectal cancer is not the only indication for a DLI. Acute complicated diverticulitis may require 
emergency sigmoidectomy, primary anastomosis and DLI. Traditionally, the more common 
procedure would have been the Hartmann’s procedure with sigmoidectomy, end colostomy, and 
closure of rectal stump but more and more surgeons are moving onto performing primary 
colorectal anastomosis, with or without a DLI. Other indications for partial colectomy and 
colorectal anastomosis that may require a protective DLI include: sigmoid volvulus, Crohn’s 
colitis, large polyps unable to be removed endoscopically, and traumatic colonic injury [8]. 
Finally, a DLI is often constructed to protect the ileal pouch anal anastomosis after a restorative 
proctocolectomy for ulcerative colitis [7,11,12]. 
 
1.3 Anastomotic leak 
 
Anastomotic leak is one of the most feared complications after primary colorectal anastomosis. 
Currently, there is no consensus on the definition of AL. A systematic review conducted by 
Bruce et al. discovered 56 different definitions of AL [13]. The International Study Group of 
Rectal Cancer classifies AL into AL requiring no active intervention (class A), AL requiring 
intervention but without re-laparotomy (class B), and AL requiring re-laparotomy (class C) [14]. 
Most surgeons would consider Class B and C AL to be clinically significant. The rate of AL after 
colorectal anastomosis ranges from 2-39% and may depend on the height of the anastomosis 
[10,15]. Estimated mortality from symptomatic AL ranges from 6 – 22% [2,10]. AL also leads to 
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reoperation in 1.5 – 2.7 % of patients and is associated with increased hospital length of stay, 
increased hospital costs, and worse oncologic outcomes [16-18]. Mirnezami et al. conducted a 
systematic review and meta-analysis of studies that assessed oncologic outcomes of colorectal 
cancer patients with AL. The authors reported that patients with ALs had significantly higher 
odds of local recurrence (OR 2.05, p = 0.0001) and significantly reduced odds of cancer specific 
survival (OR 1.64, p = 0.0001) [19]. A non-significant increase in distant recurrence was also 
reported in all seven studies that investigated this outcome [19]. Lu et al. conducted a similar but 
more recent meta-analysis that also demonstrated greater local cancer recurrence after AL (OR 
1.61, p < 0.001) but no statistically significant difference in distant recurrence [18]. 
 
Fashioning a DLI has become the standard of care for colorectal anastomoses, largely because a 
few studies have demonstrated significant benefit in overall morbidity [3,8,11,20]. Matthiessen 
et al. conducted a randomized, multicenter trial analyzing the effect of DLIs in rectal cancer 
patients undergoing LAR. One specific inclusion criteria was that the anastomosis had to be ≤ 7 
cm from the anal verge. The definition of AL used in this study was clinical: peritonitis caused 
by leakage from any staple line, rectovaginal fistula, or pelvic abscess [20]. The authors found 
that patients with DLIs had significantly fewer ALs, with a rate of 10.3% versus 28.0% (p < 
0.001) [20]. Furthermore, the DLI group had a significantly lower reoperation rate (8.6% vs. 
25.4%, p < 0.001) [20]. Mrak et al. conducted a similar study of rectal cancer patients 
undergoing low anterior resection with total mesorectal excision (TME) [3]. Patients were 
randomized to receive a DLI or no DLI. Patients in the DLI group had a lower AL rate of 5.8% 
versus 16.3% (p = 0.0441) and were also less likely to need surgical intervention for their leaks 
(20% versus 92.3%; p = 0.006) [3]. A number of retrospective observational studies have also 
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demonstrated that DLIs are associated with decreased risk of AL, although not all leaks were 
defined as symptomatic [8,11,21]. 
 
Contrarily, numerous studies have also failed to show the benefits of DLIs [2,9,22-24, 27]. 
Gastinger et al. conducted a multi-center prospective observational study looking at early 
outcome after LAR in patients with and without a protective stoma. The overall AL rate was 
similar in both groups: 14.5% for those with a stoma versus 14.2% for those without (p = 0.806) 
[2]. Patients without a protective stoma did have significantly higher reoperation rates (10.1% vs. 
3.6%, p < 0.001) [2]. However, the group with a protective stoma had significantly higher overall 
morbidity (39.7% vs. 34.4%, p = 0.007) [2]. Similarly, Maroney et al. compared the overall 6-
month complication rate between patients who underwent LAR with or without DLI and found 
that the stoma group had significantly higher complication rates (61% vs. 38%, p = 0.02) [23]. 
Inhát et al. found a 53.8% stoma related complication rate in their retrospective observational 
study [25], whereas Marusch et al. discovered significantly higher wound infection rates in 
patients with diversion stomas (7.4% vs. 2.7%, p = 0.016) [22]. There is no mortality benefit 
from DLIs [22,25-26]. 
 
Platell et al. conducted a prospective observational study on patients undergoing LAR or ultra- 
low anterior resection with DLI. In their cohort of 233 patients, 16 patients were diagnosed with 
AL (7%); seven of those patients were asymptomatic and only nine required interventions [27]. 
Ultimately, only 2 (0.9%) required reoperation. The authors concluded that > 90% of their 
patient population did not benefit from DLIs and that closure of the ileostomy added 7 days to 
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overall inpatient length of stay [27]. Similarly, Kanellos et al. recommended against routine DLI 
with LAR based on their retrospective study that demonstrated a low rate of AL [28]. 
 
1.4 Complications of defunctioning loop ileostomies 
 
There is evidence that DLIs may decrease AL, pelvic sepsis, and rate of reoperation, but DLIs 
themselves are associated with longer hospital length of stay and overall morbidity. In this 
section, we will review specific complications associated with DLIs. See Table 1 for a summary 
of current literature.  
 
1.4.1 Dehydration and acute renal failure 
 
A DLI by definition bypasses the colon entirely. The effluent released from the ileostomy has 
significantly higher water content than normal stool. Normal ileostomy output volume ranges 
from 500-1000 mL/day; however, patients can and often have increased ostomy output of up to 
2500 mL/day [29]. Such high losses are difficult for patients to replenish and manage and 
patients often present back to the hospital with acute dehydration and even acute renal failure. 
Åkesson et al. conducted a retrospective review looking at the morbidity of DLIs and found that 
32% of patients required hospital readmission secondary to stoma related complications. Further, 
29% of patients had at least one episode of dehydration of greater than 2000mL ostomy output, 
of which half required hospital readmission for intravenous fluid resuscitation and two patients 
needed admission to the intensive care unit [29]. Some research has also suggested that elderly 
patients are more prone to dehydration. For example, Paquette et al. conducted a retrospective 
cohort study that demonstrated age > 50 was associated with hospital readmission secondary to 
dehydration [30]. In 2013, Jafari et al. conducted a large population-based retrospective cohort 
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study assessing the morbidity of DLIs. Compared to the patients undergoing LAR without DLI, 
patients who had DLIs had significantly higher rates of progressive renal insufficiency (2.1% vs 
0.8% p < 0.05) [31] and a 2.37-fold increase in risk of acute renal failure (95% CI 1.21 – 4.6, p = 
0.01) [31]. Diverted patients also had significantly higher readmission rates (20.3% vs 11%, p < 
0.05) [31]. Messaris et al. demonstrated a 16.9% all-cause readmission rate after ileostomy 
creation, of which almost half were due to dehydration (7.3%) [32]. 
 
1.4.2 Stoma related complications 
 
Having a DLI itself is associated with a number of complications. Some of these include stoma 
retraction, prolapsing ostomy requiring reoperation, stenosis causing obstruction, bleeding, 
stoma necrosis, parastomal hernia, and fistula formation [23,30-31,33-37]. In a retrospective 
cohort analysis of patients with DLIs, Åkesson et al. reported a 32% hospital readmission rate 
due to stoma related complications. The majority of these readmissions (59%) were related to 
minor problems such as skin irritation, leakage from dressing, and wound infections. However, 
patients were also readmitted due to more serious complications, such as dehydration (29%), 
obstruction (14%), parastomal hernia (14%), and gastrointestinal bleed (6%) [30]. Other 
retrospective cohort studies have revealed similar rates of complications [31,33-37]. Patient 
associated morbidities that may significantly decrease quality of life have also been reported, 
including leakage from the ostomy appliance, skin excoriation, soiling and odor, and frequent 
night time emptying requirements [33]. 
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1.4.3 Morbidity associated with ileostomy reversal 
 
The reversal of a defunctioning loop ileostomy is a separate operation associated with its own 
risks. An ileostomy reversal requires resection of the ostomy and another bowel anastomosis. In 
2009, Chow et al. conducted a systematic review of 48 studies that analyzed morbidity 
associated with ostomy reversal [7]. Complications occurred in 823 out of 4765 patients giving a 
morbidity rate of 17.3%. The most common bowel related complication was small bowel 
obstruction (7.2%), with a third of these patients requiring surgical intervention [7]. Sixty 
patients suffered from anastomotic leaks (1.4%). Wound infection was the most common non-
bowel related complication at 5%. Sixty-eight patients (1.3%) developed incisional hernias 
through the stoma site. The Mortality rate was 0.4%. This large series systematic review 
demonstrated that ileostomy reversal is not benign and is associated with a low, albeit real 
mortality rate. Other retrospective cohort analyses, the most recent one being from 2016, have 
also shown similar complications following ileostomy reversal and have also reported findings of 
post-operative ileus, urinary retention, abscess formation, enterocutaneous fistula, and deep 
venous thrombosis [34,37,38,39]. 
 
1.4.4 Unwanted permanent ostomy 
 
To meet criteria for an ileostomy reversal, patients must be physiologically fit to undergo a 
second elective surgery and their colo-rectal anastomosis must be completely healed. A portion 
of patients will end up with an unwanted permanent ostomy if they do not meet these criteria. A 
number of retrospective cohort studies have analyzed the rate of permanent ileostomies after 
planned temporary ostomy. The rate ranged between 3%-25% [36,40-44]. In 2016, Kim et al. 
published a retrospective review assessing the rate of permanent stoma after rectal cancer 
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surgery [40]. Of the 673 patients that were identified as having a temporary ileostomy, 9.5% of 
these patients ended up with a permanent stoma. Within the group of patients with a permanent 
stoma, 36% never had their temporary ileostomy reversed and 64% ended up with a new 
permanent ostomy after initial ileostomy reversal [40]. Of the patients who never had their 
ileostomy reversed, the main reason was due to systemic metastatic disease, but other reasons 
included intractable anastomosis stricture, poor general condition, and patient refusal. 
Interestingly, a significant portion of patients with permanent ostomies are secondary ostomies 
due to complications after ileostomy reversal. These patients had loop ileostomies or 
colostomies. Reasons listed for a secondary permanent stoma included local recurrence, 
uncontrolled pelvic abscess, unsatisfactory anorectal function, and intractable anastomosis 
stricture [40]. Not only is a permanent ostomy associated with the risks of an ostomy as reported 
above, it can also significantly affect patients’ quality of life. 
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Table 1. Summary of retrospective and prospective studies analyzing morbidity of DLIs 
Author 
(year) N 
Overall 
morbidity SBO AKI 
Parastomal 
hernia 
Permanent 
stoma 
Åkesson 
(2012) 92 - 13% 27% 13% 11% 
Chun (2012) 123 64.2% 2.4% 13% 4.8% - 
Gessler 
(2012) 262 - 3% 18% 7% 23% 
Hallböök 
(2002) 222 - 18.5% - 18.5% - 
Hayden 
(2013) 154 - - 20% - - 
Holmgren 
(2017) 316 9% - - - 24% 
Ihnát (2016) 151 53.8% 3.8% - - - 
Jayarajah 
(2016) 192 34.2% - - - - 
Kim (2016) 673 - - - - 9.5% 
Lindgren 
(2011) 116 - - - - 19% 
Man (2016) 213 16.4% - - - - 
Pan (2013) 296 - - - - 17.2% 
Paquette 
(2013) 201 - - 17% - - 
Perez (2006) 93 17.2% 11.8%  - - 
Phatak 
(2008) 294 - - 11% - - 
Sier (2015) 485 - - - - 26% 
Waterland 
(2015) 170 - - - - 25% 
 
1.4.5 Quality of life 
 
Although not extensively studied, the presence of an ostomy, even a temporary one, can 
significantly affect quality of life (QoL). A lot of the evidence stems from direct patient 
encounters. Often, follow up patient encounters after index surgery involves discussions about 
when the ileostomy can be reversed. To date, there have only been a few longitudinal 
observational studies that have investigated QoL in patients with a temporary ileostomy, both 
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while they have the ileostomy and after reversal. In 2008, Tsunoda et al. conducted one of the 
earliest prospective longitudinal studies looking at patient QoL after low anterior resection with 
DLI [41]. The authors followed 22 patients and assessed different aspects of their QoL with the 
European Organization for Research and Treatment of Cancer (EORTC) QLQ – C30 and QLQ – 
CR38 questionnaires. Patients filled out the questionnaire at four distinct time points: before 
surgery, 2 months after resection (before ileostomy reversal), 5 months after resection, and 8 
months after resection. One benefit that the authors found was that patients’ global QoL scores 
were significantly higher after the index surgery as compared to the preoperative score, 
indicating that surgical resection of the tumor improved their overall QoL. Similarly, both future 
perspective and social function scores improved after surgery. However, patients that had an 
ileostomy had significantly lower physical function scores and role function scores at 2 months 
as compared to before surgery (p < 0.05) [41]. A similar study conducted in 2016 with a much 
larger patient population (n=120) identified similar results, demonstrating significantly lower 
role functioning, social functioning, and physical functioning after surgery and before ileostomy 
reversal [42].  
 
O’Leary et al. conducted a prospective longitudinal study that identified patients’ main concerns 
before and after low anterior resection with DLI [43]. Before surgery, patients were worried 
about the surgery itself and cancer. Twelve weeks after resection, patients’ most frequent 
concerns were stoma closure, cancer recurrence, and continued health. Six weeks after ileostomy 
closure, their principle concern was bowel function [43]. In 2011, Neuman et al. identified more 
specific patient concerns regarding the ostomy [44]. In this study, they identified a significant 
decrease in body image that continued even after stoma reversal (p = 0.03). Of the patients with 
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identified stoma related difficulties, 53% reported issues with sexual activity, 39% with leakage, 
34% with discomfort in clothing, 32% with concerns regarding privacy to empty the pouch, and 
31% reported feeling unattractive [44]. One important aspect that multiple studies discovered 
was that there was a persistent decrease in QoL even after ileostomy reversal, often associated 
with changes in bowel function and diminished body image [43-45]. In 2010, Taylor & Morgan 
published a review on QoL following reversal of temporary stoma and identified nine studies 
that assessed QoL outcomes after stoma reversal [45]. In this review, bowel function was 
identified as the principle concern of patients six weeks after ostomy closure, with frequency and 
urgency of defecation and fecal incontinence being the main symptoms. The functional bowel 
symptoms also had an impact on patients’ psychosocial health, chiefly related to altered body 
image and attractiveness. Unfortunately, Camilleri-Brennan & Steel noted that there was no 
improvement in body image even after stoma reversal [46]. 
 
1.5 Summary 
 
The utilization of defunctioning loop ileostomies after low anterior resection for rectal cancers 
has increased significantly in the past few years. There is evidence that DLIs are associated with 
decreased risk of clinically significant anastomotic leaks, but at what cost? DLIs are also 
associated with significant morbidity, from the time of formation to after closure. Furthermore, 
DLIs are associated with deteriorated quality of life. Surgeons need to consider a more selective 
utilization of DLIs in patients at high risk for anastomotic leak and explore alternative 
approaches to reduce the rate and impact of ALs. 
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1.6 Study objective 
 
The clinical controversy and equipoise are the basis of this research project. The purpose of this 
project is to identify aggregate morbidity associated with defunctioning loop ileostomy. The 
main objective of this study is to identify and analyze all morbidity associated with a 
defunctioning loop ileostomy from the onset of its creation to after its reversal, compared to 
patients without a defunctioning loop ileostomy. Perioperative outcomes of interest include: 30-
day hospital readmission, 30-day reoperation, 30-day major complications, 30-day mortality, 90-
day mortality, 1-year mortality, bleeding, and hospital length of stay during the index admission. 
Other outcomes of interest include deep space infection, bowel obstruction, hernia, acute kidney 
injury, and permanent ostomy. 
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Chapter II: Project design, methodology, and statistics 
2.1 Study design 
 
Because of the clinical equipoise identified in both the scientific literature and in clinical 
practice, the purpose of this project was to investigate the morbidity associated with 
defunctioning loop ileostomies (DLIs) within a large, population-based retrospective cohort. 
 
The Institute of Clinical and Evaluative Sciences (ICES) is a large, not-for-profit, research 
institute that has access to a number of Ontario’s health-related administrative databases. Ontario 
is one of the most populous provinces of Canada with 14.3 million residents. The healthcare for 
these patients is provided by the provincial government in a publicly funded single payer system. 
The data was obtained from the following databases: Canadian Institute for Health Information 
database (CIHI); Registered Persons Database (RPDB); Discharge Abstract Database (DAD); 
Same Day Surgery Database (SDS); National Ambulatory Care Reporting System (NACRS); 
Ontario Health Insurance Plan (OHIP) database; Ontario Cancer Registry (OCR); and the ICES 
Physician Database. All diagnoses were documented and coded using the International 
Classification of Diseases and Related Health Problems, Tenth Revision, Canada (ICD-10-CA). 
Procedural codes were also obtained from physician billings to OHIP and from Canadian 
Classification of health Interventions (CCI) codes within CIHI. 
 
2.2 Cohort identification 
 
The most common indication for a DLI is a low anterior resection (LAR). In an effort to decrease 
heterogeneity of the patient cohort, the cohort included adult patients > 18 years of age 
undergoing elective anterior resection with or without a DLI from April 1, 2002 – March 31, 
 14 
2014. The year 2002 was chosen as the start date because ICD codes were changed from version 
9 to version 10 in 2002 in Canada. The end date was chosen to allow enough time for 
observation after index surgery. 
 
Anterior resections were identified using both OHIP billing codes (S213 or S171) and CCI 
procedure codes (Appendix A).  Patients were defined as have a DLI if a billing code for 
ileostomy (S149) was also billed on the same date as the anterior resection. Patients were 
excluded if their surgery was only recorded in OHIP but not CIHI, their age or sex was 
unknown, they were a non-Ontario resident, they were < 18 years of age, they had pre-existing 
renal disease, or if they had a previous anterior resection or DLI. Rectal cancer patients were 
identified using the Ontario Cancer Registry. Patients with missing data were excluded from the 
cohort.  
 
Formal sample size calculation was not done for this study for a number of reasons. First, the 
patient cohort was expected to be quite large given that it is a population based retrospective 
analysis. The inclusion criteria for the patient cohort was set quite broadly to capture a wide 
range of patients. Second, there were numerous outcomes of interest, some were composite 
outcomes including 12 variables and no one variable was considered the main outcome of 
interest.  
 
2.3 Data collection & timeline 
 
The index event was defined as date of LAR with or without DLI. A two-year look back window 
was used to assess for patient comorbidities and a five-year look back window was used to 
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determine history of renal disease. The observation window for outcomes and ileostomy reversal 
closed one and two years after the index date, respectively (see Figure 1 for a graphical depiction 
of the data collection timeline). 
 
For patients with a DLI, a second index event was defined as the date of ileostomy reversal 
(Appendix A). A 180-day observation window was used to look for complications associated 
with the ileostomy reversal. 
 
Figure 1. Accrual, lookback, observation, and follow-up window diagram  
 
 
2.4 Baseline variables 
 
Important patient baseline variables were collected. These include patient age, sex, income 
quintile, patient Local Health Integration Network (LHIN), rurality (urban vs. rural), co- 
morbidity using John’s Hopkins Adjusted Clinical Groups Resource Utilization Bands (ACG- 
RUB) system, history of rectal cancer, history of colon cancer, stage of rectal cancer, and history 
of radiation or chemotherapy (Appendix B & C) [47]. The ACG-RUB system captures all 
morbidities for which a patient receives care during a defined period. The ACGs can be 
collapsed into six RUBs on the basis of expected use of health care resources. In this present 
study, we used the CIHI-DAD, CIHI-SDS, CIHI-NACRS, and OHIP databases to calculate 
RUBS, which were summarized as a 3-point ordinal variable: 1 = low (RUB 0-3), 2 = moderate 
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(RUB = 4), and 3 = high (RUB =5). Procedural, institutional and surgeon related variables were 
also collected, including open versus laparoscopic surgical approach, American Society of 
Anesthesiologist (ASA) classification for medical status, institution teaching status (academic 
versus community), surgeon age, surgeon annual anterior resection volume, and fiscal year 
(Appendix B & C). 
 
2.5 Defining outcomes of interests 
 
Each outcome of interest was associated with an observation window (Appendix D) and one or 
more codes (Appendix E). All outcomes of interest were defined a priori. In this study, major 
complication was a composite outcome that captured the following conditions: sepsis, 
myocardial infarction, stroke, pulmonary embolism and deep vein thrombosis, pneumonia, acute 
renal failure and renal failure requiring dialysis, atrial fibrillation/flutter, blood transfusion, 
cardiac/respiratory arrest, coma, shock, and ventilator use > 48 hrs (Appendix D). Major 
complications were assessed within 30-days of the index surgery date as well as within 30-days 
of the ileostomy reversal date. Acute kidney injury was defined as acute renal failure requiring 
hospitalization within 180 days of index surgery. The codes utilized for acute kidney injury were 
a combination of codes, some of which were validated ICD-10 codes for acute kidney injury and 
other were from the KDT variable library [48]. A bleeding complication was defined as bleeding 
severe enough to require at least one blood transfusion within 30 days of index surgery. A deep 
space infection was defined using a combination of wound infection codes plus drainage 
intervention codes; thus, only infections severe enough to require a drain were considered. 
Patients without an ileostomy reversal within two years after index surgery were considered to 
have a permanent ostomy. 
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Hospital length of stay after index surgery as well as number of days spent in hospital within 30 
days of index surgery and 1 year of index surgery were recorded (Appendix D).  
 
Anastomotic leak was an important outcome of interest of ours. However, there is no single code 
for anastomotic leak in ICD-10. Attempts were made at using surrogate codes for anastomotic 
leak such as combining codes for deep space infection with percutaneous drainage, however, the 
numbers identified were discordant with clinical reality and expectation. It was thought that the 
numbers were over-estimating rates of anastomotic leak and deemed inaccurate.  
 
2.6 Statistics and analysis 
 
Once the cohort was identified, patients were separated into two major subgroups: patients with 
rectal cancer and patients without. All analyses were conducted separately for the subgroups. 
 
Baseline differences between patients with and without DLI were evaluated using standardized 
differences (SD), Calculated as the difference in proportions divided by the standard error. A 
SD > 0.10 can be interpreted as a potentially meaningful between group difference [49]. SDs 
often provide a better indication of between group differences in large observational studies, 
where even the slightest difference can yield a significant result due to the impact of sample size 
on significance testing. Trends across the study period were assessed using the Cochran-
Armitage test for trend. 
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Unadjusted logistic regression was used to estimate the effect of DLI on all projected outcomes. 
Adjusted logistic regression was also used to control for the following variables: patient age and 
sex, expected resource utilization, history of chemotherapy or radiotherapy, ASA classification 
(ASA > 2), institution teaching status, surgeon annual volume, and fiscal year of the procedure. 
The variables chosen for adjustment were chosen a priori and were based on clinical experience 
knowing that these factors would contribute and confound a number of the outcomes of interest. 
Adjusted models used a generalized estimating equation approach with an exchangeable 
correlation structure to account for the clustering of patients within physicians and institutions. 
Outcomes are reported as odds ratios and 95% confidence intervals. Outcomes such as 30- and 
90-day mortality could not be investigated in adjusted models due to the small number of events. 
The linearity of continuous predictors was assessed using restricted cubic splines [50]. Annual 
surgeon volume demonstrated non-linearity and was dichotomized at the 50th percentile prior to 
modeling. 
 
For all analyses, reported p-values are from 2-tailed tests where a value of p < 0.05 was 
considered statistically significant. All analyses were performed using SAS EG version 7.1 (SAS 
Institute, Cary, NC, USA). 
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Part III: Results 
3.1 Baseline characteristics 
 
The initial search identified 32,200 patients from 2002-2014 that met the inclusion criteria. 
Sixty-five patients were excluded for being less than 18 years old. Four thousand and 424 
patients were excluded because they did not have a matching operation of low anterior resection 
in CIHI records. Patients with previous LAR and/or ileostomies and patients with a history of 
renal failure were also excluded, leaving a total of 25,491 patients in the overall cohort. Of the 
overall cohort, 18% (4,658) of patients had a concomitant DLI with their LAR. 
 
Patients were divided into two sub-groups on the basis of whether or not they had rectal cancer.  
The rectal cancer subgroup consisted of a total of 6,146 patients and 2,690 (43.8%) of these had 
a DLI. Patient characteristics for the rectal cancer subgroup are reported in Table 2. Stage III 
cancer was most prominent within this group (39.4%), followed by Stage I (25.8%) and Stage II 
(23.2%). Within each cancer stage, approximately half of the patients had a DLI (Table 3). 
Patients in the DLI group were more likely to have a history of radiation therapy (50% vs. 
14.9%, SD = 0.81) and chemotherapy (33.8% vs 14.9%, SD = 0.59) and were also more likely to 
have their procedure performed in a teaching institution (41.3% vs. 26.8%, SD = 0.31). 
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Table 2. Baseline characteristics for rectal cancer subgroup 
Variable 
Overall 
(n = 6,146) 
No ileostomy 
(n = 3,446) 
Ileostomy 
(n = 2,700) 
SD 
p-
value 
Patient age† 
65.0 
(57.0-73.0) 
67.0 
(58.0-75.0) 
64.0 
(56.0-72.0) 
0.21 <.001 
Patient sex (Female) 2,243 (36.5%) 1,351 (39.2%) 892 (33.0%) 0.13 <.001 
Rural residence 935 (15.2%) 513 (14.9%) 422 (15.6%) 0.02 0.421 
Income*      
Quintile 1 1,068 (17.4%) 599 (17.4%) 469 (17.4%) 0.00 0.074 
Quintile 2 1,251 (20.4%) 715 (20.7%) 536 (19.9%) 0.02 0.074 
Quintile 3 1,200 (19.5%) 713 (20.7%) 487 (18.0%) 0.07 0.074 
Quintile 4 1,307 (21.3%) 712 (20.7%) 595 (22.0%) 0.03 0.074 
Quintile 5 1,301 (21.2%) 697 (20.2%) 604 (22.4%) 0.05 0.074 
Resource Utilization      
Low 2,004 (32.6%) 1,136 (33.0%) 868 (32.1%) 0.02 0.921 
Moderate  2,377 (38.7%) 1,305 (37.9%) 1,072 (39.7%) 0.04 0.921 
High 1,765 (28.7%) 1,005 (29.2%) 760 (28.1%) 0.02 0.921 
ASA 3+ 3,528 (57.4%) 1,869 (54.2%) 1,659 (61.4%) 0.15 <.001 
Approach 634 (10.3%) 345 (10.0%) 289 (10.7%) 0.02 0.376 
Converted 273 (4.4%) 155 (4.5%) 118 (4.4%) 0.01 0.81 
Colon cancer 122 (2.0%) 77 (2.2%) 45 (1.7%) 0.04 0.113 
Rectosigmoid cancer <=5 <=5 <=5 0.03 0.211 
Radiotherapy 1,860 (30.3%) 509 (14.8%) 1,351 (50.0%) 0.81 <.001 
Chemotherapy 1,261 (20.5%) 349 (10.1%) 912 (33.8%) 0.60 <.001 
After hours procedure 168 (2.7%) 129 (3.7%) 39 (1.4%) 0.15 <.001 
Teaching status 2,037 (33.1%) 923 (26.8%) 1,114 (41.3%) 0.31 <.001 
Surgeon age† 
45.0 
(39.0-52.0) 
46.0 
(39.0-53.0) 
44.0 
(39.0-51.0) 
0.15 <.001 
Annual volume† 11.0 (6.0-18.0) 10.0 (6.0-16.0) 13.0 (7.0-21.0) 0.29 <.001 
Cancer Stageⱡ      
Stage unknown 174 (4.6%) 87 (4.9%) 87 (4.3%) 0.03 <.001 
Stage 0 16 (0.4%) 9 (0.5%) 7 (0.3%) 0.02 <.001 
Stage 1 986 (25.8%) 517 (29.0%) 469 (23.0%) 0.14 <.001 
Stage 2 887 (23.2%) 392 (22.0%) 495 (24.3%) 0.05 <.001 
Stage 3 1,504 (39.4%) 638 (35.8%) 866 (42.5%) 0.14 <.001 
Stage 4 251 (6.6%) 138 (7.7%) 113 (5.5%) 0.09 <.001 
*Missing data for 19 patients; †Median (IQR); ⱡRestricted to patients with a cancer diagnosis after April 1, 2007 
(total n=3818, exposed n=2030); SD = Standardized Difference. 
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Table 3. Stages of rectal cancer 
Cancer Stage Overall Ileostomy % 
Stage 0 16 (0.4%) 7 43.8 
Stage 1 986 (25.8%) 469 47.6 
Stage 2 887 (23.2%) 495 55.8 
Stage 3 1504 (39.4%) 866 57.6 
Stage 4 251 (6.6%) 113 45.0 
Stage NA 174 (4.6%) 87 50.0 
 
The subgroup of patients without rectal cancer included patients with colon cancer, rectosigmoid 
cancer, and patients who underwent a LAR for other indications (Table 4). There was a total of 
19,345 patients in this subgroup, of which only 1,943 (10%) received a DLI. Of the patients with 
colon cancer, only 4.5% had a DLI, whereas 17.3% of patients that had rectosigmoid cancers had 
a DLI. Similar to the rectal cancer subgroup, patients in this subgroup who received a DLI were 
also more likely to be treated in a teaching hospital and to have a history of radiation and 
chemotherapy (Table 4). 
 
3.2 Trend of defunctioning loop ileostomies 
 
When assessing the proportion of patients who underwent anterior resection with DLI, there is a 
clear upward trend over time. In 2002, only 8.5% of patients had a DLI compared to 25.5% in 
2013 (Figure 2). This increase is more pronounced in the rectal cancer group, with an increase 
from 19.1% in 2002 to 55.8% in 2013 (p < 0.0001) (Table 5). 
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Table 4. Baseline characteristics for non-rectal cancer subgroup 
Variable 
Overall 
(n = 19,345) 
No ileostomy 
(n = 17,387) 
Ileostomy 
(n = 1,958) 
SD 
p-
value 
Patient age† 
65.0 
(55.0-74.0) 
65.0 
(55.0-74.0) 
64.0 
(54.0-73.0) 
0.11 <.001 
Patient sex (Female) 9,431 (48.8%) 8,551 (49.2%) 880 (44.9%) 0.08 <.001 
Rural residence* 2,640 (13.6%) 2,317 (13.3%) 323 (16.5%) 0.09 <.001 
Income*      
Quintle 1 3,489 (18.0%) 3,084 (17.7%) 405 (20.7%) 0.07 <.001 
Quintle 2 3,876 (20.0%) 3,484 (20.0%) 392 (20.0%) 0.00 <.001 
Quintle 3 3,861 (20.0%) 3,464 (19.9%) 397 (20.3%) 0.01 <.001 
Quintle 4 4,051 (20.9%) 3,648 (21.0%) 403 (20.6%) 0.01 <.001 
Quintle 5 4,014 (20.7%) 3,657 (21.0%) 357 (18.2%) 0.07 <.001 
Resource Utilization      
Low 6,654 (34.4%) 6,063 (34.9%) 591 (30.2%) 0.10 <.001 
Moderate 7,141 (36.9%) 6,412 (36.9%) 729 (37.2%) 0.01 <.001 
High 5,550 (28.7%) 4,912 (28.3%) 638 (32.6%) 0.09 <.001 
ASA 3+ 10,484 (54.2%) 9,261 (53.3%) 1,223 (62.5%) 0.19 <.001 
Approach 1,551 (8.0%) 1,393 (8.0%) 158 (8.1%) 0.00 0.929 
Converted  1,222 (6.3%) 1,100 (6.3%) 122 (6.2%) 0.00 0.869 
Colon cancer 6,562 (33.9%) 6,261 (36.0%) 301 (15.4%) 0.49 <.001 
Rectosigmoid cancer 4,050 (20.9%) 3,349 (19.3%) 701 (35.8%) 0.38 <.001 
Radiotherapy 483 (2.5%) 199 (1.1%) 284 (14.5%) 0.51 <.001 
Chemotherapy 479 (2.5%) 261 (1.5%) 218 (11.1%) 0.40 <.001 
After hours procedure 1,490 (7.7%) 1,318 (7.6%) 172 (8.8%) 0.04 0.058 
Teaching status 4,650 (24.0%) 3,939 (22.7%) 711 (36.3%) 0.30 <.001 
Surgeon age† 
45.0 
(39.0-53.0) 
45.0 
(39.0-53.0) 
45.0 
(39.0-52.0) 
0.05 0.027 
Annual volume† 10.0 (6.0-16.0) 10.0 (6.0-16.0) 10.0 (5.0-16.0) 0.05 0.02 
*Rural and Neighbourhood income missing data for 2 and 54 patients, respectively; SD = Standardized Difference. 
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Table 5. Ileostomy timeline and trend 
Year 
No Rectal Cancer  Rectal Cancer 
Total 
n 
Ileostomy 
n 
Ileostomy % 
 Total 
n 
Ileostomy 
n 
Ileostomy % 
2002 1562 94 6.02%  392 75 19.13% 
2003 1753 106 6.05%  453 117 25.83% 
2004 1793 118 6.58%  454 129 28.41% 
2005 1775 125 7.04%  548 168 30.66% 
2006 1503 126 8.38%  481 174 36.17% 
2007 1450 135 9.31%  452 217 48.01% 
2008 1498 149 9.95%  504 246 48.81% 
2009 1594 185 11.61%  601 306 50.92% 
2010 1598 205 12.83%  553 307 55.52% 
2011 1646 254 15.43%  564 325 57.62% 
2012 1641 241 14.69%  576 319 55.38% 
2013 1532 220 14.36%  568 317 55.81% 
Overall 19345 1958 10.12%  6146 2700 43.93% 
Cochrane-Amitage trend test: p<0.0001 for both groups. 
 
Figure 2. Trend of ileostomies from 2002-2013 
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3.3 Descriptive aggregate morbidity and mortality 
 
In the overall patient cohort of 25,491 patients, 4,658 (18%) patients had DLIs. The 30-day, 90- 
day, and 1-year mortality of these patients was 1.2%, 2.2%, and 5.1%, respectively. The 30-day 
and 90-day mortality associated with ileostomy reversal was 0.6% and 0.9%, respectively. 
 
After index surgery and initial DLI, the rate of reoperation was 5.5%, hospital readmission was 
13.4%, major complication was 28.5%, deep organ/space infection requiring percutaneous 
intervention was 5.2%, acute renal failure requiring hospitalization was 10.4%, development of 
ventral hernia was 4.0%, diagnosis of bowel obstruction requiring hospitalization was 10.6%, 
bleeding requiring transfusion was 17.9%, and diagnosis of enterocutaneous fistula was 2.1% 
(Figure 3). 
 
A total of 4,041 patients (86.8%) with an initial DLI had their ileostomy reversed. After 
ileostomy reversal, the rate of major complication was 10.3%, deep organ/space infection was 
1.7%, bowel obstruction was 7.0%, diagnosis of ventral hernia was 10.3%, and diagnosis of 
colitis was 2.7% (Figure 4). 
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Figure 3. Cumulative morbidity after index surgery 
 
 
 
 
 
Figure 4. Cumulative morbidity after ileostomy reversal 
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3.4 Peri-operative outcomes compared to non-ileostomy patients 
 
The perioperative outcomes of interest all occurred within 30-days of index surgery date. The 
outcomes of interests included hospital length of stay, reoperation, readmission, major 
complication, bleeding requiring transfusion, deep space infection requiring percutaneous 
intervention, and 30-day mortality. Multi-variate analysis was performed on the following 
outcomes: reoperation, major-complication, readmission, deep organ/space infection, and 
bleeding requiring blood transfusion. 
 
3.4.1 Rectal cancer subgroup 
 
Among patients with rectal cancer, DLI was associated with higher odds of major complication 
(OR 1.24, 95% CI 1.07-1.42; p = 0.004), and hospital readmission (OR 1.57, 95% CI 1.34-1.83; 
p < 0.0001). However, DLI was also associated with lower odds of reoperation (OR 0.53, 95% 
CI 0.39-0.72; p < 0.0001). There was no difference in the rate of deep organ/space infection (OR 
0.99, 95% CI 0.73-1.35; p = 0.96) or the need for blood transfusions (OR 1.04, 95% CI 0.88-
1.23; p = 0.616) (Table 6,8-10). 
  
Although an adjusted model could not be investigated for 30-day mortality due to the small 
number of events, ileostomy was associated with a non-significant reduction in risk of 30-
mortality in an unadjusted analysis (1.2% versus 1.8%; OR 0.66, 95% CI 0.43-1.01; p = 0.05). 
Median hospital length of stay was 9 days (IQR 7-13 days) in the ileostomy group and 8 days 
(IQR 6-10 days) in the non-ileostomy group (p < 0.001) (Table 7). 
 
. 
 27 
Table 6. Adjusted and non-adjusted perioperative outcomes in the rectal cancer subgroup 
Outcome 
No ileostomy Ileostomy 
Unadjusted Adjusted 
Odds Ratio  p - 
value 
Odds Ratio  p-
value 
n = 3,446 n = 2,700 (95% CI) (95% CI) 
       
Reoperation 244 (7.1%) 121 (4.5%) 0.62 (0.49-0.77) <.0001 0.53 (0.39-0.72) <.0001 
       
Major complication 865 (25.1%) 695 (25.7%) 1.03 (0.92-1.16) 0.568 1.24 (1.07-1.42) 0.004 
       
Readmission 396 (11.6%) 508 (18.9%) 1.78 (1.55-2.05) <.0001 1.57 (1.34-1.83) <.0001 
       
Deep space 
infection 144 (4.2%) 141 (5.2%) 1.26 (1.00-1.60) 0.054 0.99 (0.73-1.35) 0.956 
       
Blood transfusion 573 (16.6%) 395 (14.6%) 0.86 (0.75-0.99) 0.033 1.04 (0.88-1.23) 0.616 
 
Table 7. Overall hospital length of stay in rectal cancer patients 
Outcome 
Overall No ileostomy Ileostomy 
p - value Mean Median Mean Median Mean Median 
(STD) (IQR) (STD) (IQR) (STD) (IQR) 
Post-operative  10.29 
8 (7-12) 
9.77 
8 (7-11) 
10.96 
9 (7-13) <.001 
length of stay (5.76) (5.69) (5.80) 
        
Total bed days 11.32 
9 (7-13) 
10.72 
8 (7-12) 
12.08 
10 (8-15) <.001 
within 30 days (6.45) (6.45) (6.38) 
        
Total bed days 19.2 
14 (8-22) 
16.3 
9 (7-17) 
22.9 
18 (13-26) <.001 
within 1 year (19.3) (19.9) (18.0) 
STD = Standard deviation, IQR = Interquartile ratio. 
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Table 8. Covariates adjusted for perioperative outcomes reoperation and major complication in 
rectal cancer patients 
Covariate 
Reoperation  Major Complication 
OR (95% CI) p-value  OR (95% CI) p-value 
Ileostomy* 0.53 (0.39-0.72) <.0001  1.24 (1.07-1.42) 0.004 
Age (per 10-year increase) 0.97 (0.88-1.06) 0.495  1.47 (1.38-1.55) <.0001 
Sex (male vs female) 1.97 (1.55-2.51) <.0001  1.07 (0.94-1.22) 0.290 
RUB (moderate vs low) 1.18 (0.87-1.61) 0.289  1.25 (1.07-1.47) 0.005 
RUB (high vs low) 1.03 (0.65-1.62) 0.900  1.30 (1.04-1.63) 0.024 
Radio or chemotherapy* 1.09 (0.83-1.44) 0.522  0.93 (0.80-1.09) 0.363 
ASA (0-2 vs 3-4) 1.06 (0.84-1.35) 0.633  1.62 (1.41-1.86) <.0001 
Teaching institution* 1.10 (0.85-1.41) 0.466  0.98 (0.84-1.15) 0.819 
High surgeon volume* 0.82 (0.66-1.02) 0.067  0.84 (0.74-0.96) 0.012 
Fiscal year (2003 vs 2002) 1.54 (0.78-3.02) 0.213  0.97 (0.72-1.31) 0.855 
Fiscal year (2004 vs 2002) 0.96 (0.48-1.90) 0.898  0.86 (0.63-1.18) 0.345 
Fiscal year (2005 vs 2002) 1.61 (0.87-3.01) 0.133  0.88 (0.65-1.21) 0.442 
Fiscal year (2006 vs 2002) 1.62 (0.85-3.07) 0.145  0.82 (0.59-1.14) 0.238 
Fiscal year (2007 vs 2002) 2.16 (1.15-4.06) 0.016  0.70 (0.50-0.99) 0.043 
Fiscal year (2008 vs 2002) 2.77 (1.53-5.02) 0.001  0.82 (0.60-1.11) 0.201 
Fiscal year (2009 vs 2002) 1.49 (0.78-2.83) 0.227  0.66 (0.47-0.92) 0.014 
Fiscal year (2010 vs 2002) 1.72 (0.91-3.26) 0.098  0.66 (0.47-0.92) 0.014 
Fiscal year (2011 vs 2002) 1.94 (1.02-3.68) 0.042  0.71 (0.52-0.98) 0.034 
Fiscal year (2012 vs 2002) 1.40 (0.72-2.70) 0.320  0.62 (0.45-0.86) 0.004 
Fiscal year (2013 vs 2002) 1.92 (1.05-3.50) 0.033  0.81 (0.60-1.10) 0.173 
*Yes vs no; OR = Odds ratio, CI = Confidence interval. 
 
 
 
 
 29 
Table 9. Covariates adjusted for perioperative outcomes readmission and deep organ infection in 
rectal cancer patients 
Covariate 
Readmission  Deep Organ Infection 
OR (95% CI) p-value  OR (95% CI) p-value 
Ileostomy* 1.57 (1.34-1.83) <.0001  0.99 (0.73-1.35) 0.956 
Age (per 10-year increase) 0.98 (0.92-1.05) 0.554  0.95 (0.86-1.05) 0.275 
Sex (male vs female) 1.01 (0.88-1.16) 0.912  1.47 (1.12-1.93) 0.006 
RUB (moderate vs low) 1.37 (1.13-1.67) 0.002  0.95 (0.66-1.37) 0.799 
RUB (high vs low) 1.47 (1.09-1.98) 0.011  1.22 (0.79-1.86) 0.371 
Radio or chemotherapy* 1.29 (1.10-1.51) 0.002  0.95 (0.70-1.28) 0.720 
ASA (0-2 vs 3-4) 1.24 (1.05-1.46) 0.010  1.12 (0.86-1.46) 0.415 
Teaching institution* 0.97 (0.83-1.14) 0.717  1.39 (1.01-1.92) 0.044 
High surgeon volume* 0.98 (0.85-1.14) 0.802  1.09 (0.83-1.44) 0.543 
Fiscal year (2003 vs 2002) 0.71 (0.44-1.14) 0.155  3.00 (0.83-10.80) 0.094 
Fiscal year (2004 vs 2002) 1.09 (0.72-1.64) 0.680  2.34 (0.60-9.07) 0.219 
Fiscal year (2005 vs 2002) 0.86 (0.55-1.34) 0.493  5.53 (1.67-18.29) 0.005 
Fiscal year (2006 vs 2002) 1.04 (0.68-1.60) 0.854  7.53 (2.3-24.68) 0.001 
Fiscal year (2007 vs 2002) 1.06 (0.68-1.66) 0.798  5.63 (1.65-19.14) 0.006 
Fiscal year (2008 vs 2002) 0.90 (0.60-1.36) 0.626  7.21 (2.18-23.84) 0.001 
Fiscal year (2009 vs 2002) 0.88 (0.58-1.34) 0.545  6.34 (1.91-21.04) 0.003 
Fiscal year (2010 vs 2002) 0.99 (0.65-1.49) 0.949  4.54 (1.32-15.62) 0.017 
Fiscal year (2011 vs 2002) 1.14 (0.76-1.71) 0.522  8.77 (2.62-29.37) 0.000 
Fiscal year (2012 vs 2002) 1.11 (0.74-1.67) 0.622  8.75 (2.67-28.62) 0.000 
Fiscal year (2013 vs 2002) 1.08 (0.70-1.65) 0.733  8.87 (2.70-29.19) 0.000 
*Yes vs no; OR = Odds ratio, CI = Confidence interval. 
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Table 10. Covariates adjusted for perioperative outcome blood transfusion in rectal cancer 
patients 
Covariate 
Blood Transfusion 
OR (95% CI) p-value 
Ileostomy* 1.04 (0.88-1.23) 0.616 
Age (per 10-year increase) 1.44 (1.34-1.53) <.0001 
Sex (male vs female) 0.77 (0.67-0.89) 0.001 
RUB (moderate vs low) 1.19 (0.99-1.43) 0.072 
RUB (high vs low) 1.11 (0.85-1.45) 0.432 
Radio or chemotherapy* 0.97 (0.80-1.17) 0.746 
ASA (0-2 vs 3-4) 1.75 (1.49-2.07) <.0001 
Teaching institution* 1.06 (0.87-1.28) 0.577 
High surgeon volume* 0.86 (0.73-1.01) 0.066 
Fiscal year (2003 vs 2002) 0.99 (0.72-1.36) 0.939 
Fiscal year (2004 vs 2002) 0.80 (0.55-1.17) 0.250 
Fiscal year (2005 vs 2002) 0.85 (0.60-1.23) 0.390 
Fiscal year (2006 vs 2002) 0.86 (0.59-1.24) 0.419 
Fiscal year (2007 vs 2002) 0.79 (0.53-1.17) 0.233 
Fiscal year (2008 vs 2002) 0.79 (0.56-1.13) 0.201 
Fiscal year (2009 vs 2002) 0.65 (0.45-0.94) 0.023 
Fiscal year (2010 vs 2002) 0.61 (0.42-0.89) 0.010 
Fiscal year (2011 vs 2002) 0.58 (0.39-0.84) 0.004 
Fiscal year (2012 vs 2002) 0.44 (0.30-0.65) <.0001 
Fiscal year (2013 vs 2002) 0.63 (0.44-0.91) 0.013 
*Yes vs no; OR = Odds ratio, CI = Confidence interval. 
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3.4.2 Non-rectal cancer subgroup 
 
Among patients without rectal cancer, DLI was associated with higher odds of reoperation (OR 
1.49, 95% CI 1.23-1.83; p < 0.0001), major complication (OR 1.59, 95% CI 1.44-1.76; p < 
0.0001), hospital admission (OR 2.38, 95% CI 2.08-2.72; p < 0.0001), deep organ/space 
infection (OR 1.67, 95% CI 1.29-2.17; p < 0.0001), and blood transfusion (OR 1.57, 95% CI 
1.39-1.76; p < 0.0001) (Table 11-14). 
 
Although a smaller percentage of patients in the ileostomy group died within 30-days of surgery, 
this difference was non-significant in an unadjusted analysis (1.2% versus 1.6%; OR 0.75, 95% 
CI 0.49-1.16; p = 0.19). Median hospital length of stay was eight (IQR 6-10) days for patients in 
the no ileostomy group and nine (IQR 8-14) days for patients in the ileostomy group (p < 0.001) 
(Table 15). 
 
Table 11. Adjusted and non-adjusted perioperative outcomes in the non-rectal cancer subgroup 
Outcome 
No ileostomy Ileostomy 
Unadjusted Adjusted 
Odds Ratio  p - 
value 
Odds Ratio  p-
value 
n = 17,387 n = 1,958 (95% CI) (95% CI) 
       
Reoperation 727 (4.2%) 133 (6.8%) 1.67 (1.38-2.02) <.0001 1.50 (1.23-1.83) <.0001 
       
Major complication 3,999 (23.0%) 632 (32.3%) 1.60 (1.44-1.77) <.0001 1.59 (1.44-1.76) <.0001 
       
Readmission 1,459 (8.4%) 363 (18.7%) 2.50 (2.20-2.83) <.0001 2.38 (2.08-2.72) <.0001 
       
Deep space 
infection 417 (2.4%) 99 (5.1%) 2.17 (1.73-2.71) <.0001 1.67 (1.29-2.17) 0.0001 
       
Blood transfusion 2,724 (15.7%) 438 (22.4%) 1.55 (1.38-1.74) <.0001 1.57 (1.40-1.76) <.0001 
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Table 12. Covariates adjusted for perioperative outcomes reoperation and major complication in 
non-rectal cancer patients 
Covariate Reoperation  Major Complication 
OR (95% CI) p-value  OR (95% CI) p-value 
Ileostomy* 1.50 (1.23-1.83) <.0001  1.59 (1.44-1.76) <.0001 
Age (per 10-year increase) 1.04 (0.98-1.09) 0.229  1.33 (1.28-1.37) <.0001 
Sex (male vs female) 1.61 (1.40-1.86) <.0001  0.77 (0.72-0.83) <.0001 
RUB (moderate vs low) 1.01 (0.84-1.21) 0.959  1.15 (1.05-1.26) 0.002 
RUB (high vs low) 1.15 (0.92-1.44) 0.222  1.44 (1.29-1.60) <.0001 
Colon/rectosigmoid cancer* 0.83 (0.71-0.96) 0.016  0.93 (0.86-1.00) 0.050 
ASA (0-2 vs 3-4) 1.35 (1.16-1.58) <.0001  1.99 (1.83-2.16) <.0001 
Teaching institution* 1.27 (1.05-1.54) 0.015  1.45 (1.25-1.68) <.0001 
High surgeon volume* 0.73 (0.63-0.84) <.0001  0.84 (0.77-0.91) <.0001 
Fiscal year (2003 vs 2002) 0.84 (0.6-1.18) 0.315  0.91 (0.78-1.06) 0.233 
Fiscal year (2004 vs 2002) 1.00 (0.71-1.41) 0.992  0.85 (0.72-1.00) 0.057 
Fiscal year (2005 vs 2002) 0.88 (0.62-1.25) 0.484  0.87 (0.75-1.01) 0.061 
Fiscal year (2006 vs 2002) 1.09 (0.78-1.54) 0.612  0.81 (0.68-0.95) 0.010 
Fiscal year (2007 vs 2002) 1.27 (0.93-1.73) 0.139  0.78 (0.64-0.93) 0.007 
Fiscal year (2008 vs 2002) 1.30 (0.92-1.84) 0.136  0.78 (0.66-0.92) 0.003 
Fiscal year (2009 vs 2002) 1.21 (0.87-1.7) 0.265  0.67 (0.57-0.80) <.0001 
Fiscal year (2010 vs 2002) 1.19 (0.85-1.66) 0.304  0.71 (0.60-0.84) <.0001 
Fiscal year (2011 vs 2002) 1.03 (0.73-1.46) 0.848  0.74 (0.63-0.88) 0.001 
Fiscal year (2012 vs 2002) 1.19 (0.84-1.67) 0.337  0.74 (0.62-0.87) 0.001 
Fiscal year (2013 vs 2002) 0.98 (0.70-1.39) 0.918  0.79 (0.66-0.94) 0.008 
*Yes vs no; OR = Odds ratio, CI = Confidence interval. 
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Table 13. Covariates adjusted for perioperative outcomes readmission and blood transfusion in 
non-rectal cancer patients 
Covariate 
Readmission  Blood Transfusion 
OR (95% CI) p-value  OR (95% CI) p-value 
Ileostomy* 2.38 (2.08-2.72) <.0001  1.57 (1.4-1.76) <.0001 
Age (per 10-year increase) 1.03 (0.99-1.07) 0.142  1.29 (1.24-1.34) <.0001 
Sex (male vs female) 0.94 (0.85-1.04) 0.194  0.62 (0.57-0.67) <.0001 
RUB (moderate vs low) 1.22 (1.08-1.39) 0.002  1.10 (0.99-1.21) 0.074 
RUB (high vs low) 1.45 (1.24-1.69) <.0001  1.36 (1.20-1.54) <.0001 
Colon/rectosigmoid cancer* 0.93 (0.84-1.03) 0.136  0.97 (0.89-1.05) 0.437 
ASA (0-2 vs 3-4) 1.21 (1.09-1.35) 0.00  1.99 (1.81-2.19) <.0001 
Teaching institution* 1.26 (1.11-1.43) 0.00  1.52 (1.28-1.80) <.0001 
High surgeon volume* 0.92 (0.83-1.03) 0.14  0.80 (0.72-0.87) <.0001 
Fiscal year (2003 vs 2002) 1.19 (0.93-1.52) 0.164  0.88 (0.74-1.04) 0.141 
Fiscal year (2004 vs 2002) 1.17 (0.92-1.49) 0.19  0.86 (0.72-1.03) 0.101 
Fiscal year (2005 vs 2002) 1.09 (0.84-1.41) 0.514  0.83 (0.70-0.98) 0.026 
Fiscal year (2006 vs 2002) 0.86 (0.65-1.13) 0.271  0.77 (0.63-0.94) 0.008 
Fiscal year (2007 vs 2002) 1.21 (0.93-1.56) 0.155  0.68 (0.54-0.84) 0.000 
Fiscal year (2008 vs 2002) 1.41 (1.09-1.82) 0.008  0.71 (0.58-0.86) 0.001 
Fiscal year (2009 vs 2002) 1.03 (0.79-1.34) 0.855  0.65 (0.54-0.79) <.0001 
Fiscal year (2010 vs 2002) 1.23 (0.94-1.60) 0.128  0.63 (0.52-0.77) <.0001 
Fiscal year (2011 vs 2002) 1.04 (0.8-1.34) 0.768  0.68 (0.56-0.83) 0.000 
Fiscal year (2012 vs 2002) 1.05 (0.81-1.36) 0.711  0.58 (0.47-0.70) <.0001 
Fiscal year (2013 vs 2002) 1.15 (0.89-1.49) 0.300  0.62 (0.50-0.76) <.0001 
*Yes vs no; OR = Odds ratio, CI = Confidence interval. 
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Table 14. Covariates adjusted for perioperative outcome deep organ infection in non-rectal 
cancer patients 
Covariate 
Deep Organ Infection 
OR (95% CI) p-value 
Ileostomy* 1.67 (1.29-2.17) 0.000 
Age (per 10-year increase) 0.93 (0.86-0.99) 0.031 
Sex (male vs female) 1.47 (1.21-1.77) <.0001 
RUB (moderate vs low) 1.18 (0.92-1.51) 0.190 
RUB (high vs low) 1.41 (1.06-1.88) 0.019 
Colon/rectosigmoid cancer* 0.86 (0.72-1.04) 0.116 
ASA (0-2 vs 3-4) 1.31 (1.08-1.60) 0.007 
Teaching institution* 1.80 (1.42-2.29) <.0001 
High surgeon volume* 0.86 (0.70-1.05) 0.126 
Fiscal year (2003 vs 2002) 0.88 (0.46-1.68) 0.694 
Fiscal year (2004 vs 2002) 1.06 (0.62-1.80) 0.834 
Fiscal year (2005 vs 2002) 1.38 (0.79-2.42) 0.256 
Fiscal year (2006 vs 2002) 1.60 (0.93-2.75) 0.093 
Fiscal year (2007 vs 2002) 2.20 (1.29-3.77) 0.004 
Fiscal year (2008 vs 2002) 2.34 (1.38-3.97) 0.002 
Fiscal year (2009 vs 2002) 2.11 (1.27-3.50) 0.004 
Fiscal year (2010 vs 2002) 1.76 (0.99-3.11) 0.054 
Fiscal year (2011 vs 2002) 2.37 (1.43-3.91) 0.001 
Fiscal year (2012 vs 2002) 2.32 (1.39-3.87) 0.001 
Fiscal year (2013 vs 2002) 2.24 (1.32-3.77) 0.003 
*Yes vs no; OR = Odds ratio, CI = Confidence interval. 
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Table 15. Overall hospital length of stay in non-rectal cancer patients 
Outcome 
Overall No ileostomy Ileostomy 
p - value Mean Median Mean Median Mean Median 
(STD) (IQR) (STD) (IQR) (STD) (IQR) 
Post-operative  9.17 
8 (6-10) 
8.89 
8 (6-10) 
11.63 
9 (8-14) <.001 
length of stay (5.31) (5.11) (6.30) 
        
Total bed days 9.82 
8 (6-11) 
9.48 
8 (6-10) 
12.80 
11 (8-16) <.001 
within 30 days (5.89) (5.68) (6.84) 
        
Total bed days 14.4 
9 (7-15) 
13.2 
8 (6-14) 
25.1 
19 (14-29) <.001 
within 1 year (16.9) (15.8) (21.4) 
STD = Standard deviation, IQR = Interquartile ratio. 
 
3.5 Long-term outcomes compared to non-ileostomy patients 
 
Long-term outcomes were captured within 180 days of the index surgery and included acute 
renal failure requiring hospitalization, bowel obstruction requiring hospital admission, abdominal 
hernia, enterocutaneous fistula, and 90-day and 1-year mortality. 
 
3.5.1 Rectal cancer subgroup 
 
DLIs were associated with significantly higher rates of acute renal failure requiring 
hospitalization (OR 4.15, 95% CI 3.14-5.47; p < 0.0001). One-year mortality was lower in rectal 
cancer patients with DLIs, although the difference was not statistically significant (OR 0.77, 95% 
CI 0.56-1.00; p = 0.05) (Table 16, 18). 
 
For unadjusted outcomes of rectal cancer patients, 90-day mortality was significantly lower in 
the ileostomy group (OR 0.66, 95% CI 0.47-0.92; p = 0.01). However, ileostomy patients did 
have much higher odds of ventral hernia (OR 2.4, 95% CI 1.66-3.46; p < 0.0001) and bowel 
 36 
obstruction (OR 14.5, 95% CI 9.72-21.57; p < 0.0001). There was no between group difference 
in the number of enterocutaneous fistulas (OR 0.64, 95% CI 0.34-1.19; p = 0.15) (Table 17). 
 
Table 16. Unadjusted and adjusted long-term outcomes in rectal cancer patients 
Outcome 
No 
ileostomy 
Ileostomy 
Unadjusted Adjusted 
Odds Ratio  p - 
value 
Odds Ratio  
p-value 
n = 3,446 n = 2,700 (95% CI) (95% CI) 
       
Renal failure 90 (2.6%) 
272 
(10.1%) 4.18 (3.27-5.33) <.0001 4.15 (3.14-5.47) <.0001 
       
Mortality (1 
year) 233 (6.8%) 121 (4.5%) 0.64 (0.52-0.81) 0.000 0.77 (0.59-1.00) 0.004 
 
Table 17. Unadjusted long-term outcomes for rectal cancer patients; after ileostomy reversal 
Outcome 
Overall 
No 
Ileostomy 
Ileostomy 
OR (95% CI) p-value 
n=6,146 n=3,446 n=2,700 
Mortality (90-
day) 
155 
(2.5%) 
102 (3.0%) 53 (2.0%) 0.66 (0.47-0.92) 0.014 
Ostomy-related 
complication 
454 
(7.4%) 
96 (2.8%) 358 (13.3%) 5.33 (4.23-6.72) <.0001 
Ventral hernia 
128 
(2.1%) 
45 (1.3%) 83 (3.1%) 2.4 (1.66-3.46) <.0001 
Bowel 
obstruction or 
ileus 
304 
(4.9%) 
27 (0.8%) 277 (10.3%) 14.48 (9.72-21.57) <.0001 
Enterocutaneous 
fistula 
45 
(0.7%) 
30 (0.9%) 15 (0.6%) 0.64 (0.34-1.19) 0.154 
OR = Odds ratio, CI = Confidence interval. 
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Table 18. Co-variates adjusted for long-term outcomes in rectal cancer patients 
Covariate 
Mortality (1-year)  Renal Failure 
OR (95% CI) p-value  OR (95% CI) p-value 
Ileostomy* 0.77 (0.59-1.00) 0.053  4.15 (3.14-5.47) <.0001 
Age (per 10-year increase) 1.63 (1.45-1.84) <.0001  1.49 (1.35-1.65) <.0001 
Sex (male vs female) 1.64 (1.28-2.10) 0.000  1.32 (1.03-1.69) 0.03 
RUB (moderate vs low) 1.16 (0.89-1.51) 0.287  1.18 (0.87-1.60) 0.283 
RUB (high vs low) 1.27 (0.87-1.85) 0.212  1.06 (0.68-1.65) 0.798 
Radio or chemotherapy* 0.99 (0.75-1.30) 0.933  1.14 (0.91-1.43) 0.272 
ASA (0-2 vs 3-4) 1.89 (1.42-2.51) <.0001  1.65 (1.27-2.13) 0.000 
Teaching institution* 0.75 (0.56-1.00) 0.047  0.83 (0.63-1.08) 0.168 
High surgeon volume* 0.91 (0.70-1.16) 0.436  1.04 (0.83-1.29) 0.759 
Fiscal year (2003 vs 2002) 0.74 (0.41-1.33) 0.313  0.72 (0.30-1.78) 0.481 
Fiscal year (2004 vs 2002) 0.90 (0.55-1.50) 0.694  1.53 (0.74-3.15) 0.254 
Fiscal year (2005 vs 2002) 0.76 (0.45-1.28) 0.307  1.18 (0.54-2.54) 0.683 
Fiscal year (2006 vs 2002) 0.64 (0.36-1.12) 0.116  1.37 (0.67-2.83) 0.388 
Fiscal year (2007 vs 2002) 0.89 (0.51-1.54) 0.676  1.21 (0.56-2.59) 0.626 
Fiscal year (2008 vs 2002) 0.79 (0.44-1.39) 0.407  1.52 (0.72-3.21) 0.269 
Fiscal year (2009 vs 2002) 0.57 (0.32-1.02) 0.059  1.37 (0.68-2.76) 0.373 
Fiscal year (2010 vs 2002) 0.61 (0.34-1.09) 0.093  1.30 (0.63-2.65) 0.479 
Fiscal year (2011 vs 2002) 0.66 (0.38-1.14) 0.135  1.36 (0.67-2.77) 0.401 
Fiscal year (2012 vs 2002) 0.65 (0.39-1.09) 0.102  2.09 (1.05-4.16) 0.037 
Fiscal year (2013 vs 2002) 0.56 (0.31-1.00) 0.050  2.05 (1.05-4.00) 0.036 
*Yes vs no; OR = Odds ratio, CI = Confidence interval. 
 
3.5.2 Non-rectal cancer subgroup 
 
Among patient without rectal cancer, DLIs were also associated with significantly higher odds of 
acute renal failure (OR 5.76, 95% CI 4.66-7.12; p < 0.0001). There was no significant difference 
in one-year mortality (OR 1.15, 95% CI 0.93-1.41; p = 0.20) (Table 19, 20). 
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In terms of unadjusted outcomes, while 90-day mortality did not differ between the groups (OR 
1.00, 95% CI 0.74-1.35; p = 0.99), patients with an ileostomy did have significantly higher odds 
of ventral hernia (OR 2.37, 95% CI 1.90-2.97; p < 0.0001), bowel obstruction (OR 44.5, 95% CI 
32.46-61.15; p < 0.0001, and enterocutaneous fistula (OR 2.53, 95% CI 1.98-3.23; p < 0.0001) 
(Table 21). 
 
Table 19. Unadjusted and adjusted long-term outcomes in non-rectal cancer patients 
Outcome 
No 
ileostomy 
Ileostomy 
Unadjusted Adjusted 
Odds Ratio  p - 
value 
Odds Ratio  
p-value 
n = 17,387 n = 1,958 (95% CI) (95% CI) 
       
Renal failure 348 (2.0%) 
212 
(10.8%) 5.95 (4.97-7.10) <.0001 5.76 (4.66-7.12) <.0001 
       
Mortality (1 
year) 988 (5.7%) 117 (6.0%) 1.60 (1.44-1.77) 0.590 1.15 (0.93-1.42) <.200 
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Table 20. Covariates adjusted for long-term outcomes in non-rectal cancer patients 
Covariate 
Mortality (1-year)  Renal Failure 
OR (95% CI) p-value  OR (95% CI) p-value 
Ileostomy* 1.15 (0.93-1.42) 0.200  5.76 (4.66-7.12) <.0001 
Age (per 10-year increase) 1.72 (1.60-1.85) <.0001  1.53 (1.40-1.66) <.0001 
Sex (male vs female) 1.21 (1.05-1.39) 0.008  1.23 (1.05-1.45) 0.013 
RUB (moderate vs low) 0.97 (0.82-1.14) 0.698  1.17 (0.94-1.45) 0.166 
RUB (high vs low) 1.24 (1.04-1.49) 0.019  1.58 (1.23-2.04) 0.000 
Colon/rectosigmoid* 1.33 (1.14-1.55) 0.000  0.98 (0.82-1.18) 0.818 
ASA (0-2 vs 3-4) 2.17 (1.87-2.51) <.0001  1.93 (1.56-2.38) <.0001 
Teaching institution* 1.07 (0.88-1.30) 0.498  1.08 (0.87-1.35) 0.465 
High surgeon volume* 0.85 (0.74-0.97) 0.017  1.13 (0.94-1.36) 0.200 
Fiscal year (2003 vs 2002) 0.96 (0.72-1.27) 0.766  0.96 (0.57-1.60) 0.865 
Fiscal year (2004 vs 2002) 0.79 (0.60-1.06) 0.112  1.18 (0.70-1.97) 0.541 
Fiscal year (2005 vs 2002) 0.88 (0.68-1.14) 0.342  1.01 (0.61-1.66) 0.984 
Fiscal year (2006 vs 2002) 0.69 (0.52-0.93) 0.013  1.14 (0.71-1.83) 0.586 
Fiscal year (2007 vs 2002) 0.72 (0.54-0.97) 0.028  1.16 (0.72-1.89) 0.542 
Fiscal year (2008 vs 2002) 0.54 (0.40-0.75) 0.000  1.33 (0.81-2.18) 0.265 
Fiscal year (2009 vs 2002) 0.63 (0.46-0.85) 0.003  1.36 (0.82-2.25) 0.239 
Fiscal year (2010 vs 2002) 0.61 (0.45-0.82) 0.001  1.50 (0.95-2.35) 0.080 
Fiscal year (2011 vs 2002) 0.70 (0.53-0.93) 0.013  2.01 (1.3-3.11) 0.002 
Fiscal year (2012 vs 2002) 0.46 (0.33-0.63) <.0001  1.65 (1.02-2.65) 0.040 
Fiscal year (2013 vs 2002) 0.49 (0.36-0.68) <.0001  1.88 (1.22-2.90) 0.004 
*Yes vs no; OR = Odds ratio, CI = Confidence interval. 
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Table 21. Unadjusted long-term outcomes for non-rectal cancer patients 
Outcome 
Overall No Ileostomy Ileostomy 
OR (95% CI) p -value 
n = 19, 345 n - 17,387 n = 1958 
Mortality (90-day) 484 435 49 
1.00 (0.74-1.35) 0.999 
 (2.5%) (2.5%) (2.5%) 
Ventral hernia 491 390 101 
2.37 (1.90-2.97) <.0001 
 (2.5%) (2.2%) (5.2%) 
Bowel obstruction 263 48 215 44.55 (32.46-
61.15) 
<.0001 
 (1.4%) (0.3%) (11.0%) 
Ostomy related 
complications 1082 714 368 5.41 (4.72-6.19) <.0001 
 (5.6%) (4.1%) (18.8%) 
Enterocutaneous 
fistula 387 303 84 2.53(1.98-3.23) <.0001 
  (2.0%) (1.7%) (4.3%) 
OR = Odds ratio, CI = Confidence interval. 
 
3.6 Timing of ileostomy reversal and permanent ostomies 
 
Out of 4658 patients that had DLIs, 4041 patients had ileostomy reversals, leaving 617 (13.2%) 
patients with a permanent ileostomy. The mean time to reversal was 231 days (STD 125 days) 
and the median time to reversal was 214 days (IQR 133-301 days). The majority of patients had 
their ileostomy reversed between 3 and 12 months (76.9%). Ten percent of patients had their 
ileostomy reversed very early (before 3 months) and the rest (13.1%) had their reversal between 
12-24 months (Table 22). 
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Table 22. Timing of ileostomy reversals 
Time to reversal n 
Number 
of 
patients 
at each 
interval 
Cumulative 
% of all 
patients 
with an 
ileostomy 
Individual 
% at each 
interval with 
a reversal 
Cumulative 
% of patients 
with a 
reversal 
Within 1 month 16 16 0.34% 0.39% 0.40% 
Within 3 months 391 375 8.39% 9.28% 9.68% 
Within 6 months 1559 1168 33.47% 28.90% 38.58% 
Within 9 months 2706 1147 58.09% 28.38% 66.96% 
Within 12 months 3499 793 75.12% 19.62% 86.59% 
Within 15 months 3808 309 81.75% 7.65% 94.23% 
Within 18 months 3940 132 84.59% 3.27% 97.50% 
Within 24 months 4041 101 86.75% 2.50% 100.00% 
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Chapter IV: Discussion 
4.1 Clinical dilemma 
 
Defunctioning loop ileostomies (DLIs) are one of the most common procedures performed by 
general surgeons and colorectal surgeons, and their utilization is on the rise. According to data 
from study, there was a 300% increase in the number of DLIs performed in Ontario from 2002 to 
2013 (Figure 2). DLIs became popular after a number of randomized controlled trials (RCTs) 
demonstrated its benefit in decreasing symptomatic anastomotic leaks (AL) after low anterior 
resection (LAR), and especially as surgeons began to perform lower resections to preserve 
sphincter function [3,20,51]. However, their use has been extended beyond the indications of 
those RCTs and some surgeons are forming them whenever they’re not confident about the 
anastomosis. As more DLIs are being used, surgeons are beginning to see more complications 
associated with these ileostomies, both in clinical practice and in clinical research 
[9,25,26,29,31,35-37,52]. 
 
Although there have been studies analyzing the morbidity associated with DLIs, none of these 
studies followed the same patients from inception of the ostomy to ileostomy reversal. This is 
one of the main strengths of the current study. Most studies were also conducted in a 
retrospective nature; however, the databases utilized for the current study used population-level 
data [26,31,52]. Another strength of this study is that we used administrative databases that 
collect all available patient data, making it a real-life representation of the patient cohort in the 
time period selected. To our knowledge, this is one of the largest patient cohorts to date to 
investigate outcomes following DLI. 
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One of the biggest limitations of this retrospective analysis, which is important to address before 
interpretation of the outcomes, is the heterogeneous nature of the patient cohort. In an effort to 
produce a powerful study to allow for multivariate analysis, the definition of the patient cohort 
was set widely. Any patient undergoing LAR was included. The indications for surgery varied, 
ranging from cancer resections, to diverticular disease, to trauma, to inflammatory bowel disease. 
To accommodate some of the heterogeneity, two major adjustments were made: first, patients 
were separated into subgroups of rectal cancer patients versus non-rectal cancer patients and 
second, multivariate analysis was used to adjust for confounding factors. Overall, these 
adjustments made the rectal cancer subgroup quite a homogenous cohort of patients. It is 
possible that rectal cancer patients undergo LAR for other reasons, but, for the vast majority of 
patients, it can be inferred that these patients underwent surgery for cancer resection. The other 
subgroup, however, remains heterogeneous and includes colon cancer patients along with 
patients without cancer. These patients were not excluded from the study because their data still 
provides valuable information on the frequency of complications associated with DLIs. 
Nevertheless, results from this subgroup should be interpreted with caution. 
 
4.2 Overall morbidity and mortality 
 
The overall morbidity identified in this study is quite significant and was comparable to 
outcomes from previous studies, including three other large database cohort studies assessing 
morbidity and mortality of patients with a LAR and diverting ostomy [26,31,52,53] (Table 23). 
The overall morbidity observed in the current study was 28.5%. In Nurkin et al.’s retrospective 
cohort study, patients that underwent low pelvic anastomosis had an overall morbidity of 15.8%, 
and patients that underwent coloanal anastomosis had an overall morbidity of 11.4% [26] (Table 
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23). A substantial proportion of patients also experience major complications after ileostomy 
reversal, including10.3% in this study and 9.3% as reported by Sharma et al. [53] (Table 23). 
Rates of reoperation, deep space infection, and 30-day mortality were similar in the current study 
(Table 23). The rate of acute kidney injury (AKI) observed in this study is much higher than the 
rate reported in previous studies, although Jafari et al. and Nurkin et al. both reported that DLI 
was associated with increased risk of AKI (OR 2.37, 95% CI 1.22-4.58; p = 0.011; OR 3.67) 
[26,31]. A number of smaller retrospective studies reported similar or higher rates of AKI: 
14.5% by Åkesson et al., 18% by Gessler et al., 20.1% by Hayden et al., and 17% Paquette et al. 
[29,30,36,54]. 
 
Table 23. Large population retrospective cohort studies and cumulative morbidity 
Author (year) N 
Major 
complication 
Re-
operation AKI 
Deep space 
infection 
30-day 
mortality 
Yang (current) 4,658 28.5% 5.5% 10.4% 5.2% 1.2% 
Jafari (2013) 991 - 4.5% 1.3% 7.5% 1.3% 
Nurkin 
(2013a) 606 15.8% 5.1% 2.3% 5.6% 1.0% 
Nurkin 
(2013b) 352 11.4% 1.7% 2.3% 5.1% 0% 
Chow (2009) 6107 17.3% - - 5.0% 0.4% 
After ileostomy reversal         
Yang (current) 4,041 10.3% - - 1.7% 0.6% 
Sharma (2013 5,401 9.3% 4.0% - - 0.6% 
Note: Nurkin 2013a included low pelvic anastomosis, Nurkin 2013b included coloanal anastomosis 
 
4.3 Rectal cancer patients 
 
In the current study, rectal cancer patients who underwent a LAR with DLI demonstrated 
significantly lower rates of reoperation (OR 0.53, 95% CI 0.39-0.72; p < 0.0001) and 90-day 
mortality (OR 0.66, 95% CI 0.47-0.92; p = 0.01). Although reoperation may be required for 
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several reasons, AL is one of the main indications for a reoperation within 30 days of DLI. Most 
other immediate post-operative complications do not require an operation. For example, wound 
infections and abscesses can be treated with antibiotics and percutaneous drains. If the rate of 
reoperation is interpreted as a surrogate indicator for significant AL requiring operative 
intervention, then our results suggest that DLIs are protective against ALs. This finding is 
consistent with a number of previous studies. Mattheson et al. conducted one of the first RCTs 
comparing the rate of symptomatic AL in patients undergoing LAR with or without a 
defunctioning ostomy [20]. In this study, defunctioning stomas included both ileostomies and 
colostomies. The defunctioned group had a significantly lower rate of symptomatic anastomotic 
leakage as compared to the non-defunctioned group (10.3% vs 28.0%, OR 3.4, 95% CI 1.6-6.9, p 
< 0.001) [20]. Pisarska et al. conducted a recent systematic review and meta-analysis analyzing 
the role of DLI in rectal cancer surgery [55]. This study included a total of 2,366 patients from 
13 studies, 4 of which were RCTs while 9 were comparative studies. The meta-analysis of RCTs 
demonstrated a relative risk (RR) reduction of 0.43 in the DLI group (95% CI 0.28-0.67, I2 
=35%) [55]. Meta-analysis of the comparative studies also showed a RR reduction of 0.49 (95% 
CI 0.27-0.87, I2 = 42%) [55]. In 2013, Jafari et al. conducted a similar large population 
retrospective cohort study that included 6,337 patients from the National Surgery Quality 
Improvement Project (NSQIP) database [31]. The authors reported that the 991 (16%) patients 
who received a DLI were significantly less likely to require reoperation than those without an 
ileostomy (4.5% vs 6.9%, p < 0.05) [31]. 
 
The decrease in 90-day mortality identified in this study may be attributed to its protective effect 
against AL. Matthiessen et al. conducted a retrospective cohort study assessing mortality after 
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elective anterior resection [56]. Out of 6,833 patients, 140 died within 30 days of their initial 
hospital stay [56]. These 140 patients were analyzed and compared against a randomly chosen 
control group selected from the remaining 6,693 patients. Within that cohort, 59 patients had 
documented AL and the leak was considered to be the cause of death or an indirect contributor to 
the patient’s demise [56]. Multivariate analysis in this study demonstrated that male sex, age, 
Dukes’ stage D, intraoperative adverse events, and anastomotic leak were all independent risk 
factors for post-operative death [56]. Therefore, Matthiessen et al. concluded that AL is highly 
associated with mortality [56]. 
 
The 90-day mortality benefit has not been widely reported in previous studies. The only study 
that has demonstrated a mortality benefit from a protective ostomy was by Gastinger et al. [2]. 
They analyzed the data from a prospective multicenter study conducted between January 2000 
and December 2001. This study included 2,729 patients and 881 of them underwent a protective 
stoma after LAR. The protective stoma included both colostomies and ileostomies. In this study, 
the group with a protective ostomy had a significantly lower in-hospital mortality rate (0.9% vs 
2.0%, p = 0.037) [2]. Most other studies have not demonstrated a significant difference in risk of 
mortality [25,31,55,57]. The most recent systematic review and meta-analysis was done by 
Pisarska et al. [55]. The meta-analysis of both RCTs and comparative non-randomized studies 
did not demonstrate a significant benefit in terms of mortality (OR 1.12, 95% CI 0.71, 1.77, p = 
0.39 for RCTs and OR 1.16, 95% CI 0.70, 1.94; p = 0.56 for comparative studies) [55]. Even a 
larger systematic review on diverting ostomies that included both colostomies and ileostomies by 
Montedori et al. did not demonstrate a mortality benefit [15]. Only RCTs were included in this 
systematic review and only three studies reported on mortality. Meta-analysis demonstrated an 
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odds ratio of 0.58 with a 95% CI 0.14, 2.33, p = 0.44 for mortality [15]. Therefore, the majority 
of evidence in the literature suggests that defunctioning ostomies do not provide a mortality 
benefit; however, the number of studies reporting mortality was limited and none of them 
analyzed mortality beyond 30 days. The current study followed patients for up to two years after 
the index surgery and captured mortality for up to one-year after surgery. The rate of reoperation 
was lower in the DLI group. Anecdotally, patients rarely die within 30-days of their index 
surgery, especially if they are taken back to the operating room and have a prolonged hospital 
stay. It is feasible that the mortality benefit of defunctioning ostomies was not identified in 
previous studies due to the short follow up intervals. 
 
The protective effects of DLIs is contrasted with high rates of morbidity, as we found that DLIs 
were significantly associated with increased risk of major complication, hospital readmission, 
longer hospital length of stay, hospital admission for AKI, ventral hernia, and bowel obstruction. 
Similar complications have been noted in previous studies [2,7,9,25,29,36,37,54,58-59]. This 
prompts the debate about whether the benefits of DLI out-weighs the morbidity. For cancer 
patients, AL not only worsens post-operative outcome, morbidity, and mortality, it also worsens 
oncologic prognosis [16-18]. Therefore, ALs should be minimized as much as possible. The 
absolute risk of AL for the average rectal cancer patients has been revisited many times 
throughout the years and the risk is not as high as previously thought. Currently, an anastomotic 
leak rate of < 8% is considered acceptable [10]. Chun et al. conducted a retrospective cohort 
study looking at patient characteristics associated with higher risk for AL and concluded that risk 
factors include male sex (OR 8.56), obesity with BMI > 30 (OR 8.56), age > 65 years (OR 
53.34), and hypertension (OR 8.36) [58].  
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In Nurkin et al.’s large population retrospective cohort analysis, they analyzed patients with low 
pelvic anastomosis and coloanal anastomoses separately [26]. Patients with a low pelvic 
anastomosis with or without a DLI did not have significantly different rates of morbidity 
(pneumonia, unplanned intubation, pulmonary embolus, myocardial infarction, bleeding, deep 
vein thrombosis, sepsis, septic shock, reoperation, or wound complications) or mortality [26]. 
The DLI group did, however, have a higher rate of AKI (OR 3.67) [26]. The coloanal group had 
more complications in patients without a diverting ostomy, including higher rates of unplanned 
intubation (OR 8.48), ventilation > 48 h (OR 3.67), bleeding (OR 8.31), septic shock (OR 2.48), 
reoperation (OR 7.11), and serious morbidity (OR 2.35) [26]. This suggests that patients with 
coloanal anastomosis may benefit from a DLI, whereas this may not be true for patients with a 
low pelvic anastomosis [26]. 
 
One of the most notable complications seen with DLIs is acute kidney injury (AKI). To our 
knowledge, every study that has analyzed complications related to ostomies has demonstrated 
significantly higher risk of AKI [25,26,31,33,34,36,51,53,58,60]. The rate of AKI after 
ileostomy ranges from 11% - 43%, with the current study reporting a rate of 10.4%. AKI is 
common with an ileostomy because of high ostomy output. The ostomy bypasses the water-
absorbing functionality of the colon, thus leading to high volume loss. Often, patients have a 
difficult time keeping up with the necessary fluid intake, resulting in dehydration and pre-renal 
AKI. The clinical significance of an AKI is quite significant. Not only does it contribute to 
increased health-care utilization and cost, it also puts these patients at risk for chronic kidney 
injury [61-62]. Although no study has followed patients long enough to assess for long-term 
sequelae of AKI secondary to high ileostomy output, O’Connor et al. conducted a systematic 
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review looking at long-term outcomes in patients who developed AKI after abdominal surgery. 
Specifically, they identified a 12.6 relative risk of death in patients who developed AKI [61]. 
Paquette et al. assessed the impact of readmission due to dehydration after DLI [33]. For patients 
admitted for dehydration, they stayed a median of 1 day with a range of 1-3 days. For patients 
admitted for renal failure, patients stayed a median of 4 days with a range of 3-7 days [33]. The 
cost on the healthcare system per patient was $2,750 USD for dehydration and $9,107 USD for 
renal failure [33]. 
 
4.4 Non-rectal cancer patients 
 
In the current study, the subgroup of patients without rectal cancer was a heterogeneous group of 
patients. Their specific indications for index surgery could have been discordant, including 
cancer resection, diverticular disease, resection for inflammatory bowel disease, volvulus, or 
trauma. Conclusions made with respect to this subgroup may be biased due to confounding 
factors; however, it was still interesting to analyze the results. From this patient cohort, no 
associated benefit was seen in the ileostomy group and the ileostomy cohort had significantly 
more complications including higher risk of major complication, reoperation, readmissions, 
blood transfusion, deep space infection requiring percutaneous intervention, acute renal failure 
requiring hospitalization, bowel obstruction, and ventral hernia (Table 6). There is very limited 
utilization for DLIs other than for cancer resections. The only consideration existing in current 
literature for performing a LAR with primary anastomosis and DLI is for complicated 
diverticulitis [63-67]. For complicated diverticulitis, the historic gold standard procedure is a 
Hartmann’s procedure, which is a LAR and end colostomy, leaving a rectal stump [63-67]. An 
end colostomy can be difficult to reverse and requires a second laparotomy, whereas a DLI is an 
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easier reversal surgery that can be done locally at the site of the ostomy. Constantinides et al. 
showed 27% of patients with a Hartmann’s end colostomy never got reversed as opposed to 8% 
of patients with a DLI [65]. Therefore, in current practice, the preferred procedure for 
diverticulitis is often a LAR with primary anastomosis with or without a defunctioning loop 
ileostomy. Gawlick & Nirula used the NSQIP database and conducted a retrospective cohort 
analysis on patients who underwent Hartmann’s procedure versus primary anastomosis and DLI 
[63]. In this study, primary anastomosis with diverting ileostomy was associated with 
significantly higher mortality in patients with dirty/infected wounds (OR 2.02, 95% CI 1.06- 
3.85) [63]. There was no significant difference in wound infection, wound dehiscence, or post- 
operative sepsis. When looking solely at septic patients without dirty/feculent wounds, there was 
no difference in mortality between the groups [63]. Therefore, this study recommended safe 
utilization of primary anastomosis with diverting ileostomy for complicated diverticulitis without 
feculent contamination [63]. To our knowledge, no studies have been conducted investigating the 
morbidity associated with DLIs in diverticulitis patients. 
 
4.5 Permanent ostomies 
 
In this patient cohort, 13.2% patients were left with a permanent ostomy, which was defined as 
no evidence of ileostomy reversal at two-years after index surgery. This is comparable to other 
studies in the literature where the estimated rate of permanent ileostomies ranges from 11-25% 
[36,40,43,59,68-69]. This is quite significant: more than 1 out of 10 patients who planned to have 
a temporary ostomy never have it reversed. This has a significant impact on overall patient 
quality of life (QoL) [41,43-44]. Survey studies have shown that ostomies are associated with 
decreased physical function and role function, significant concern regarding the ostomy, 
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significantly decreased confidence in body image, and issues with discomfort, feeling 
unattractive and decreased sexual activity [41,43-44]. These studies also demonstrate a persistent 
decrease in QoL even after ileostomy reversal, often associated with changes in bowel function 
and diminished body image [41,43-45]. 
 
There are complications that can occur with a defunctioned colon, such as diversion colitis. The 
term diversion colitis was coined in 1981 in Glotzer et al.’s case series of ten patients with 
inflammation of a de-functioned segment of bowel [70]. The specific pathophysiology is 
unknown but there are two theories. The main theory is that the lack of short-chain fatty acids 
(SCFA) in the diverted colon causes the inflammation [71-75]. Colonocytes rely on SCFAs as 
the main source of nutrient [71-75]. Symptoms can include watery diarrhea, lower abdominal 
discomfort/pain, pelvic pain, anorectal pain, rectal bleeding, tenesmus, mucous discharge, and 
low-grade fever [71-73]. The majority of patients experience mild to moderate symptoms but 4% 
will present with severe symptoms [71,73]. The only definitive treatment is re-establishing 
continuity [71-72]. 
  
In the current study, the majority of reversals occurred between 3-12 months after index surgery 
(76.9%). Thirteen percent had their ileostomy reversed between 1-2 years after surgery and 9.6% 
got an early ileostomy reversal before 3 months (Table 9). Timing of ileostomy reversal is an 
important consideration in the operative planning process. An ileostomy that has been there for 
longer is harder and takes longer to reverse [76]. Furthermore, it has been shown that a colon that 
has been defunctioned for a longer period of time will take longer to regain function, leading to 
slower recovery from ileostomy reversal and longer hospital length of stay [76]. 
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4.6 Timing of ileostomy reversal 
Timing of ileostomy reversal often depends on whether patients will be undergoing post- 
operative chemotherapy. Chemotherapy usually lasts between 3 to 6 months and, anecdotally, 
surgeons wait 4-6 weeks after chemotherapy to let patients recover before reversing the 
ileostomy. Because of the issues associated with late reversal, it has been proposed that an ultra- 
early closure be done close to index surgery (within 14 days after index surgery) [77-78]. Two 
recent systematic reviews and meta-analyses have investigated this specific question. Farag et al. 
performed a systematic review and meta-analysis of four randomized controlled trials with a 
total of 446 patients (176 in the early closure group and 270 in delayed closure group) [77]. They 
identified similar risk of anastomotic leak (RR 0.37, 95% CI 0.10-1.42, p = 0.15), anastomotic 
stenosis (RR 4.79, 95% CI 0.23-09.47, p = 0.31), and post-operative complications (RR 0.75, 
95% CI 0.48-1.16, p = 0.19) between patients with early reversal and late reversal [77]. There 
was also no significant difference in the duration of operation (mean difference 0.49, 95% CI -
1.09-0.12, p = 0.12) or hospital length of stay (mean difference -0.44, 95% CI -0.25-0.18, p = 
0.75) [80]. They concluded that early ileostomy reversal within 14 days was not associated with 
higher risk than delayed reversal; however, they also did not demonstrate any significant benefit 
associated with early reversal [77]. Menahem et al. also conducted a systematic review that 
included comparative studies assessing early closure (≤ 14 days) versus late closure (>8 weeks) 
[78]. The meta-analysis included six studies, including two retrospective case series, one 
prospective case series, and three RCTs [78]. In the analysis, there was no significant difference 
in overall morbidity (OR 0.98, 95% CI 0.63-1.53; p = 0.95), anastomotic leak (OR 0.63, 95% CI 
0.22-1.78; p = 0.38), or reoperation (OR 1.06, 95% CI 0.50-2.26; p = 0.88) [78]. There was 
significantly less small bowel obstruction (OR 0.46, 95% CI 0.24-0.86; p = 0.02) and stoma-
 53 
related complications (OR 0.11, 95% CI 0.06-0.20; p < 0.00001) in the early closure group [78]. 
Patients in the early closure group did have a significantly higher overall wound infection rate 
(OR 3.83, 95% CI 2.14-6.86; p < 0.00001). The level of evidence in Menahem’s meta-analysis 
was arguably lower than Farag et al. due to higher heterogeneity; however, neither study 
demonstrated worse outcomes in terms of anastomotic leak or post-operative complications. In 
fact, Menahem et al. demonstrated benefit with less bowel obstruction and stoma-related 
complications [78]. This is an avenue that should be explored further in clinical practice. 
 
4.7 Highly selective utilization of defunctioning ileostomies 
There is no question that there is benefit with the DLI as demonstrated by this study and a 
number of studies in the past [3,15,20,22,26,]. However, the rate of DLI formation has increased 
perhaps too dramatically. There are significant risks associated as well [7,9,23-27,29-31,33-40]. 
The most important message from this study is that the benefits of a DLI does not always 
outweigh the risks and perhaps too many people are getting DLIs when they don’t need it. Platell 
et al. conducted a prospective observational study in 2005 and followed 233 patients at their 
center that underwent low or ultra-low anterior resections with DLI [27]. In this cohort, 16 (7%) 
of patients had an anastomotic leak, 7 (3%) were asymptomatic, and 9 (4%) required 
intervention; but only 2 (0.9%) patients required re-operation for their anastomotic leak [27]. The 
authors concluded that > 90% of their patient cohort had a DLI but did not benefit from it [27].  
 
When analyzing the absolute risk reduction seen in this study, there is a 1% absolute risk 
reduction (ARR) of 90-day mortality in rectal cancer patients, a 2.3% ARR of 1-year mortality, 
and a 2.6% ARR of re-operation associated with DLIs. When this is converted to numbers 
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needed to treat, 100 rectal cancer patients would need to have a DLI to reduce one mortality at 
90 days; 43 patients to decrease one mortality at 1 year; and 38 patients to decrease one re-
operation at 30 days. For the patients that would not benefit from the DLI and are now exposed 
to the risks of DLIs, this can be a significant risk. Therefore, the next step is to determine who is 
at highest risk for anastomotic leak and only selectively utilize DLIs in that patient population.  
 
In Nurkin et al.’s retrospective database analysis, patients with low pelvic anastomosis did not 
demonstrate benefit from their DLI but patients with coloanal anastomosis did worse without a 
DLI [26]. Therefore, the authors recommended DLIs for coloanal anastomosis. Shiomi et al. 
conducted a prospective observational study analyzing rates of AL with or without a diverting 
ostomy stratified by the level of anastomosis [79]. In this study, they identified that patients had 
significantly more leaks if their anastomosis was < 5cm from the anal verge. They also found 
that tumour size and the lack of a diverting ostomy were independently associated with risk of 
AL (ref). Therefore, they recommend DLI with any anastomosis < 5cm from the anal verge [79]. 
Zhang et al. conducted a multicenter analysis of risk factors for AL after middle or low rectal 
cancer resection [80]. All of their patients underwent rectal cancer resection without a diverting 
ostomy. Of those, 11.9% developed symptomatic class B or C AL. Of the patients that leaked, 
55% required an operation [80]. They then analyzed a number of patient variables to determine 
which variables were associated with a higher risk of AL. The variables included: gender, age, 
history of diabetes, ASA classification, K-ras status of cancer, distance of tumor from anal verge 
(> 7 ≤ 10 or ≤ 7 cm), histopathologic grade, TNM staging, tumor size (< 5cm or ≥ 5cm), 
preoperative chemoradiation therapy, BMI (< 25 or ≥ 25), hemoglobin level (≥ 110 or < 110), 
albumin level (≥ 35 or < 35), laparoscopic approach, operation time (≤ 180 mins or > 180 mins), 
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and blood loss (< 400mL or ≥ 400mL). Of those, male gender, distance of tumor from the anal 
verge ≤ 7 cm, preoperative chemoradiation therapy, K-ras mutation of the tumor, and diabetes 
mellitus were all significantly associated with a higher risk of leak. They also identified that male 
gender and blood loss ≥ 400mL was independently associated with AL requiring re-operation 
[80]. These factors identified should be utilized to develop an algorithm or scoring system to 
determine which patients should get a DLI.  
 
Blok et al. conducted an interesting prospective cohort comparative trial to a historical control 
looking at morbidity after rectal cancer surgery [81]. One group is the historic group who 
routinely underwent laparoscopic low anterior resection with total mesorectal excision, stapled 
anastomosis and a DLI. The other group of patients all underwent a transanal total mesorectal 
excision, stapled anastomosis with suture re-enforcement, and highly selective use of DLIs. 
Overall, the historic group with routine use of DLIs stayed in hospital significantly longer [6 
days (IQR 5-11 days) vs. 5 days (IQR 4-6 days); p < 0.001] [81]. There was no significant 
difference in overall complication, surgical complication, readmission rate, or re-intervention 
rate [81]. When they assessed ostomy specific outcomes, 80% of the highly selective group of 
patients never had a DLI vs. 8% in the other group (p < 0.001). The highly selective group also 
had significantly less total complications related to ostomies (13% vs 49%, p < 0.001), ostomy 
related readmissions (15% vs 84%, p < 0.001), and ostomy related reoperations (15% vs. 86%, p 
< 0.001) [81].  This study is not perfect – the patient cohorts had different types of surgeries, 
despite being similar demographically. However, it did demonstrate that patients’ post-operative 
morbidity was not higher without a DLI and thus, highly selective use of DLIs is feasible.  
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4.8 Alternatives to defunctioning ileostomies 
 
Other alternatives to a diverting ileostomy have been described in the literature. Two techniques 
described include the ghost ileostomy (GI) and endoluminal trans-anastomotic tube [82-86]. 
Ghost ileostomies have been previously described but are not currently a widely accepted 
practice. A GI is when a silastic band is placed around a loop of terminal ileum and the band is 
brought up through the abdominal wall and secured at the level of the skin (Figure 5) [82]. This 
allows surgeons the opportunity to mature a loop ileostomy locally, without having to perform a 
laparotomy if needed; but if no ileostomy is required, the silastic band can easily be removed, 
akin to removing a surgical drain [82]. In a study conducted by Miccini et al., when they 
described this technique, 11% of their cohort had their GI converted to a loop ileostomy due to 
diagnosis of anastomotic leak [82]. They reported no complications related to the GI and that 
maturing the ostomy was easy and safe [82]. Mori et al. conducted a retrospective cohort study 
evaluating the outcomes of using the technique of GIs and identified 168 patients that underwent 
total mesorectal excision (TME) with GI [83]. Twenty patients developed anastomotic leaks. In 
13 of those patients, an ileostomy was fashioned under local anesthesia without the need for re-
laparotomy [83]. The ileostomy led to resolution of the clinical signs of infection and closure of 
the anastomotic dehiscence. The only complication identified was that one patient had twisting 
of the ileal loop around the mesentery, resulting in bowel occlusion requiring reoperation [83]. 
Of the 168 patients that had a GI, 53 (91.2%) did not end up having an ileostomy. The authors of 
this study concluded that GIs, along with a highly selective stoma policy, would be a safe option 
for patients with low pelvic anastomoses [83]. 
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Figure 5. Ghost ileostomy 
 
The second, less invasive, technique that has been described in the literature is leaving an 
endoluminal transanal tube in situ above the anastomosis after surgery [84-86]. Xiao et al. 
conducted a single institution RCT of patients undergoing low anterior resection for biopsy 
proven rectal cancer [84]. Patients were randomized to endoluminal tube (sutured in place and 
left for 5-7 days post-operatively) or no tube [84]. The primary outcome of interest was 
symptomatic AL. They found that patients in the endoluminal tube group had significantly fewer 
ALs as compared to patients in the control group (4.0% vs 9.6%, p = 0.026) [84]. Two other 
retrospective cohort studies have analyzed the efficacy of endoluminal transanal tubes [85,86]. In 
Hidaka et al.’s retrospective cohort study, 4.2% versus 13.8% of patients with and without a 
transanal tube had an AL, respectively (p < 0.05) [85]. Furthermore, the reoperation rate for 
symptomatic AL was 0% in the intervention group and 73.3% in the control group (p < 0.05) 
[85]. Yang’s study did not demonstrate a significant difference between the rates of AL (9.8% vs 
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11.8%, p = 0.652), however, patients in the transanal tube group were significantly less likely to 
require reoperation for AL (2.9% vs 11.8%, p = 0.016) [86]. These studies suggest that a 
transanal rectal tube left in situ after low anterior resection is associated with decreased risk of 
reoperation for AL and may potentially decrease the overall risk of AL [84-86]. 
 
A third consideration, although not widely described and may be controversial, is to take a page 
from history and consider putting high risk patients on bowel rest and parenteral nutrition post-
operatively. This was widely practiced historically with bowel resections before the advent of 
enhanced recovery after surgery (ERAS). Patients will be in hospital longer on index admission 
but would avoid the morbidities of a DLI as well as a second surgery of ileostomy reversal. 
Currently, there is no evidence for this proposed method but it would be an interesting option to 
explore.  
 
Although the ghost ileostomy and transanal rectal tube approaches have not gained wide-spread 
popularity amongst surgeons, existing studies demonstrate promising results. Further 
investigations with Level I evidence should be pursued. 
 
4.7 Limitations 
 
As previously discussed, there was heterogeneity in the patient cohort, especially in the non-
rectal cancer subgroup, which limits the definitive conclusions that can be made from the 
comparative analysis. 
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One of other biggest limitations of this study was the inability to detect ALs. Until recently, there 
was no specific code for AL. Therefore, documentation of AL in these administrative databases 
was not accurate. Attempts were made at combining different codes, such as the code of wound 
infection with percutaneous drainage or the code for wound infection combined with reoperation, 
but the results did not make clinical sense. This is the disadvantage of the administrative 
databases used for this study. A similar study conducted by Jafari et al. using the NSQIP 
database also could not report on anastomotic leak outcomes [31]. There was only one other 
retrospective database cohort study that was able to assess anastomotic leak and it was based on 
a prospectively maintained database in Japan [87]. Anastomotic leak is one of the most relevant 
clinical outcome measures when it comes to DLIs and not being able to accurately analyze its 
relationship to DLIs was a big limitation of this study. 
 
Confounding by indication was a limitation of this retrospective study. Although we tried to 
control for multiple factors that may influence our outcomes, we still could not account for every 
single variable. For example, one important piece of information that we could not gather was 
the location of tumor in rectal cancer patients. There is strong evidence suggesting that low 
tumors and low anastomosis benefit from DLIs [10,26]. Therefore, surgeons would perform 
DLIs in patients with lower tumors. This inherently could have contributed to more morbidity 
outcomes that we could not adjust for.  
 
At the onset of cohort identification, we set exclusion criteria that did exclude a number of 
patients from the overall cohort in an effort to decrease heterogeneity. A total of 6,675 patients 
met exclusion criteria and was eliminated from the patient cohort. Their missing data could have 
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confounded and added heterogeneity to the cohort but we also lost some information from these 
patients by excluding them.  
 
Finally, majority of the codes used in the study were not validated. The codes chosen by the 
research group may not have been the most accurate codes to use, but majority of the outcomes 
assessed did not have associated validated codes. In situations where there were validated codes, 
such as with acute kidney injury, the validated codes were used.  
 
4.8 Current recommendations & future directions 
 
Currently, there are no defined guidelines on when it is appropriate to give patients a DLI. 
Textbooks provide little guidance and quote basic indications of DLIs as to divert the colon, to 
evacuate stool if the colon has been removed, or to relieve bowel obstruction [88]. However, 
little guidance is provided as to when it is appropriate to divert the colon, especially knowing 
that DLIs are not benign entities. In 2015, the American Society of Colorectal Surgeons 
(ASCRS) has a clinical guideline for ostomy surgery [89]. The guidelines recognize that there is 
significant morbidity associated with ostomies and provides evidence-based recommendations 
on how to fashion an ostomy to decrease morbidity. However, again, they do not provide any 
guidance on when it is appropriate to give a patient a DLI. 
  
This current study has identified a benefit of DLIs in the rectal cancer patients with lower rates 
of reoperation and decreased mortality. As discussed, this likely correlates with previous studies 
demonstrating that DLIs are associated with decreased risk of clinically significant anastomotic 
leaks. This benefit, however, was not seen in the non-rectal cancer group. Other considerations 
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should be taken into account such as history of radiation therapy, level of tumor, and other 
patient baseline characteristics. It would be beneficial if surgical societies collated all available 
information on DLIs to produce a set of guidelines and criteria to assist surgeons in the decision 
making as to whether or not to give their patients a DLI. 
 
There have been alternatives to long-term ileostomies that can be explored further. Some of these 
include early ileostomy reversal, ghost ileostomies (GI), and endoluminal trans-anastomotic 
tubes. There is evidence in the current literature demonstrating potential in these alternative 
techniques. These should be explored further in both clinical practice and clinical research. 
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Chapter V: Conclusion 
A large population, real-life, retrospective patient cohort study was conducted to analyze the 
aggregate morbidity associated with defunctioning loop ileostomies. The only benefit seen 
associated with DLIs was a decrease in the risk of perioperative reoperation, 90-day mortality, 
and 1-year mortality in rectal cancer patients. There were significant complications associated 
with DLIs, including longer hospital length of stay and increased risk of major complication, 
acute kidney injury requiring hospitalization, hospital readmission, ventral hernia, and bowel 
obstruction, as well as a 13% permanent ostomy rate. There is certainly a role for DLIs to 
decrease risk of significant anastomotic leak requiring intervention and/or operation; however, 
DLIs are not benign entities. Based on the results of this study, it can be argued that highly 
selective utilization of DLIs should be recommended. We also observed an increasing trend of 
DLI utilization in the general surgery community. This trend should be questioned and 
scrutinized. Other factors should also be taken into consideration, such as patient comorbidities, 
age, and technical challenges during surgery. 
 
What should be defined as “low” enough to quality for DLI warrants further investigation. It 
would also be beneficial if surgical societies collated information from all available evidence to 
come up with a guideline and possibly even a scoring system to guide surgeons in their clinical 
decision making.  
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Appendix A 
Appendix A Codes for low anterior resection, ileostomy, and ileostomy reversal 
Codes for anterior resection 
   
type code Fee Code Description 
FEECODE S171 INTESTINE-EXC-LT.HEMICOLECTOMY WITH ANT.RESECT/ANAST. ETC. 
  S213 
RECTUM-EXC.-PROCTECTOMY-ANTERIOR 
RESECT./PROCTOSIGMOIDECTOMY 
    
INCODE 1NK77EN 
Bypass with exteriorization, small intestine endoscopic [laparoscopic] approach end 
enterostomy (e.g. terminal, end or loop ileostomy) 
  1NK77RR 
Bypass with exteriorization, small intestine open approach end enterostomy (e.g. terminal, 
end or loop ileostomy) 
  1NK77RRXXG 
Bypass with exteriorization, small intestine open approach continent ileostomy using 
pedicled flap 
  1NM87DE 
Excision partial, large intestine endoscopic [laparoscopic, laparoscopic-assisted, hand-
assisted] approach colorectal anastomosis technique 
  1NM87DF 
Excision partial, large intestine endoscopic [laparoscopic, laparoscopic-assisted, hand-
assisted] approach colocolostomy anastomosis technique 
  1NM87RD Excision partial, large intestine open approach Colorectal anastomosis technique 
  1NM87RN Excision partial, large intestine open approach Colocolostomy anastomosis technique 
  1NQ87DA 
Excision partial, rectum endoscopic [laparoscopic, laparoscopic-assisted, hand-assisted] 
approach closure by apposition technique [e.g. suturing, stapling] or no closure required 
(for tissue regenerat 
  1NQ87DE 
Excision partial, rectum endoscopic [laparoscopic, laparoscopic-assisted, hand-assisted] 
approach colorectal anastomosis technique 
  1NQ87DF 
Excision partial, rectum endoscopic [laparoscopic] approach colorectal anastomosis 
technique 
  1NQ87DX 
Excision partial, rectum endoscopic [laparoscopic, laparoscopic-assisted, hand-assisted] 
approach stoma formation with distal closure 
  1NQ87LA 
Excision partial, rectum open abdominal [e.g. anterior] approach closure by apposition 
technique [e.g. suturing, stapling] or no closure required (for tissue regeneration) 
  1NQ87RD 
Excision partial, rectum open abdominal [e.g. anterior] approach colorectal anastomosis 
technique 
  1NQ87TF 
Excision partial, rectum open abdominal approach [e.g. anterior] stoma formation with 
distal closure 
  1NQ89KZ Excision total, rectum abdominoperineal approach coloanal  anastomosis technique 
  1NQ89KZXXG Excision total, rectum abdominoperineal approach pouch formation 
  1NQ89SF Excision total, rectum abdominal [anterior] approach coloanal anastomosis technique 
  1NQ89SFXXG Excision total, rectum abdominal [anterior] approach pouch formation 
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PRCODE 6051 ANTERIOR RESECTION WITH CONCOMITANT COLOSTOMY 
  6052 OTHER ANTERIOR RESECTION 
  6053 POSTERIOR RESECTION 
  6054 DUHAMEL RESECTION 
  6055 HARTMANN RESECTION 
  6059 OTHER RESECTION OF RECTUM NEC 
   
   
Code for ileostomy  
type code Fee Code Description 
FEECODE S149 INTESTINE-INC.-ENTEROTOMY-ILEOSTOMY 
   
   
Codes for ileostomy reversal 
type code Fee Code Description 
FEECODE S185 
INTESTINE-SUT/CLOSURE-COLOSTOMY/ENTEROSTOMY-W/OUT 
RESEC/ANAS 
  
INCODE 1NK82DP 
Reattachment, small intestine endoscopic [laparoscopic] approach of enteroenterostomy 
[diversionary] 
  1NK82EN Reattachment, small intestine endoscopic [laparoscopic] approach of ileostomy 
  1NK82RF Reattachment, small intestine open approach of enteroenterostomy [diversionary] 
  1NK82RR Reattachment, small intestine open approach of ileostomy 
  
PRCODE 5851 CLOSURE OF INTESTINAL STOMA, UNQUALIFIED 
  5852 CLOSURE OF STOMA OF SMALL INTESTINE 
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Appendix B 
Appendix B. Definitions of patient demographics and source of information 
Variable Data Sources Window Reporting Detail 
Patient Variables  
Patient Age RPDB Indexdt Mean (SD), Median (IQR) 
Patient Sex RPDB Indexdt N (%) each category 
Income 
quintile 
RPDB Indexdt N (%) each quintile 
Patient LHIN RPDB Indexdt N (%) each category 
Rurality (rural 
vs. urban) 
RPDB Indexdt N (%) rural, urban, missing 
ACG RUG DAD/SDS/NACRS/OHIP Indexdt – 2 years to index 
admdate – 1 day 
 
(18-mo lookback for 
NACRS) 
N (%) low (RUB = 0-3), 
moderate (RUB = 4), high 
(RUB = 5) 
Rectal Cancer OCR From inception of data to 
indexdt + 90 days 
N (%) 
Cancer Stage OCR n/a N (%) 0, 1, 2, 3, 4 
Hx of 
radiotherapy 
OHIP Indexdt – 120 days to 
indexdt 
N (%) 
Hx of 
chemotherapy 
OHIP Indexdt – 120 days to 
indexdt 
N (%) 
Procedure, Institution, and Surgeon Variables 
Surgical 
approach 
DAD Index date N (%) open, laparoscopic 
ASA 3-to-5 OHIP Index date N (%) yes 
Institution 
teaching status 
(Academic vs. 
non-academic) 
DAD/SDS -- N (%) academic 
Surgeon age IPDB Index date Mean (SD), Median (IQR) 
Surgeon 
annual anterior 
resection 
volume 
OHIP Fiscal year of the indexdt Mean (SD), Median (IQR) 
Fiscal year DAD/SDS Index date N (%) each year 
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Appendix C 
Appendix C. Other Codes 
type code description 
DX10CODE N17 Acute renal failure 
  N170 Acute renal failure with tubular necrosis 
  N171 Acute renal failure with acute cortical necrosis 
  N172 Acute renal failure with medullary necrosis 
  N178 Other acute renal failure 
  N179 Acute renal failure, unspecified 
  
DXCODE 5845 LOWER NEPHRON NEPHROSIS 
  5846 AC RENAL FAIL, CORT NECR 
  5847 AC REN FAIL, MEDULL NECR 
  5848 AC RENAL FAILURE NEC 
  5849 ACUTE RENAL FAILURE NOS 
Acute renal failure codes 
 
type code Fee Code Description 
FEECODE G093 Haemodiafiltration - Contin. Init & Acute (repeatx3) 
  G095 Slow Continuous Ultra Filtration - Initial & Acute (repeat) 
  G294 ARTERIOVENOUS SLOW CONT. ULTRAFILTRATN-INIT& ACUTE 
  G295 CONT. ARTERIOVENOUS HAEMOFILTRAT'N - INIT. & AC. (MAX 3) 
  G323 D./T. PROC.-DIALYSIS-HAEMODIALYSIS-ACUTE,REPEAT 
  G330 D./T. PROC.-DIALYSIS-PERITONEAL-ACUTE (UP TO 48 HRS) 
  G331 D./T. PROC.-DIALYSIS-PERITONEAL-REPEAT ACUTE (UP TO 48 HRS) 
  G866 INTERMITTENT HEMODIAL AUX TREAT CTRE(PER TREAT) 
  R849 D./T. PROC.-DIALYSIS-HEMO-INITIAL AND ACUTE 
Dialysis codes 
 
type code Fee Code Description 
FEECODE E016 
PATIENTS ASA 5 - MORIBUND PT NOT EXPECTED TO 
LIVE 
  E017 PATIENTS ASA 4 - PATIENT WITH INCAPACITATING 
  E022 PATIENTS ASA 3 
ASA codes 
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type code 
Description of this dxcode 
suffix 
type combination 
DX10CODE E1020 Type 1 diabetes mellitus with incipient diabetic nephropathy 
  E10200 Type 1 diabetes mellitus with incipient diabetic nephropathy, adequately controlled with diet or oral agent 
  E10201 Type 1 diabetes mellitus with incipient diabetic nephropathy, adequately controlled with insulin 
  E10202 
Type 1 diabetes mellitus with incipient diabetic nephropathy, inadequately controlled with diet or oral agents (and 
insulin not used to stabilize) 
  E10203 
Type 1 diabetes mellitus with incipient diabetic nephropathy, inadequately controlled with diet or oral agents but 
adequately controlled with insulin 
  E10204 Type 1 diabetes mellitus with incipient diabetic nephropathy, inadequately controlled with insulin 
  E10209 Type 1 diabetes mellitus with incipient diabetic nephropathy, level of control unspecified 
  E1021 Type 1 diabetes mellitus with established diabetic nephropathy 
  E10210 Type 1 diabetes mellitus with established diabetic nephropathy, adequately controlled with diet or oral agent 
  E10211 Type 1 diabetes mellitus with established diabetic nephropathy, adequately controlled with insulin 
  E10212 
Type 1 diabetes mellitus with established diabetic nephropathy, inadequately controlled with diet or oral agents 
(and insulin not used to stablize) 
  E10213 
Type 1 diabetes mellitus with established diabetic nephropathy, inadequately controlled with diet or oral agents 
but adequately controlled with insulin 
  E10214 Type 1 diabetes mellitus with established diabetic nephropathy, inadequately controlled with insulin 
  E10219 Type 1 diabetes mellitus with established diabetic nephropathy, level of control unspecified 
  E1022 Type 1 diabetes mellitus with end-stage renal disease [ESRD] 
  E10220 Type 1 diabetes mellitus with end-stage renal disease [ESRD], adequately controlled with diet or oral agents 
  E10221 Type 1 diabetes mellitus with end-stage renal disease [ESRD], adequately controlled with insulin 
  E10222 
Type 1 diabetes mellitus with end stage renal disease [ESRD], inadequately controlled with diet or oral agents 
(and insulin not used to stabilize) 
  E10223 
Type 1 diabetes mellitus with end stage renal disease [ESRD], inadequately controlled with diet or oral agents but 
adequately controlled with insulin 
  E10224 Type 1 diabetes mellitus with end stage renal disease [ESRD], inadequately controlled with insulin 
  E10229 Type 1 diabetes mellitus with end stage renal disease [ESRD], level of control unspecified 
  E1023 Type 1 diabetes mellitus with established or advanced kidney disease 
  E1028 Type 1 diabetes mellitus with other specified kidney complication not elsewhere classified 
  E10280 Type 1 diabetes mellitus with other specified renal complication, adequately controlled with diet or oral agents 
  E10281 Type 1 diabetes mellitus with other specified renal complication, adequately controlled with insulin 
  E10282 
Type 1 diabetes mellitus with other specified renal complication, inadequately controlled with diet or oral agents 
(and insulin not used to stabilize) 
  E10283 
Type 1 diabetes mellitus with other specified renal complication, inadequately controlled with diet or oral agents 
but adequately controlled with insulin 
  E10284 Type 1 diabetes mellitus with other specified renal complication, inadequately controlled with insulin 
  E10289 Type 1 diabetes mellitus with other specified renal complication, level of control unspecified 
  E10290 Type 1 diabetes mellitus with renal complication unspecified, adequately controlled with diet or oral agents 
  E10291 Type 1 diabetes mellitus with renal complication unspecified, adequately controlled with insulin 
  E10292 
Type 1 diabetes mellitus with renal complication unspecified, inadequately controlled with diet or oral agents (and 
insulin not used to stabilize) 
  E10293 
Type 1 diabetes mellitus with renal complication unspecified, inadequately controlled with diet or oral agents but 
adequately controlled with insulin 
  E10294 Type 1 diabetes mellitus with renal complication unspecified, inadequately controlled with insulin 
  E10299 Type 1 diabetes mellitus with renal complication unspecified, level of control unspecified 
  E1120 Type 2 diabetes mellitus with incipient diabetic nephropathy 
  E11200 Type 2 diabetes mellitus with incipient diabetic nephropathy, adequately controlled with diet or oral agents 
  E11201 Type 2 diabetes mellitus with incipient diabetic nephropathy, adequately controlled with insulin 
  E11202 
Type 2 diabetes mellitus with incipient diabetic nephropathy, inadequately controlled with diet or oral agents (and 
insulin not used to stabilize) 
  E11203 
Type 2 diabetes mellitus with incipient diabetic nephropathy, inadequately controlled with diet or oral agents but 
adequately controlled with insulin 
  E11204 Type 2 diabetes mellitus with incipient diabetics nephropathy, inadequately controlled with  insulin 
  E11209 Type 2 diabetes mellitus with incipient diabetics nephropathy, level of control unspecified 
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  E1121 Type 2 diabetes mellitus with established diabetic nephropathy 
  E11210 Type 2 diabetes mellitus with established diabetic nephropathy, adequately controlled with diet or oral agents 
  E11211 Type 2 diabetes mellitus with established diabetic nephropathy, adequately controlled with insulin 
  E11212 
Type 2 diabetes mellitus with established diabetic nephropathy, inadequately controlled with  diet or oral agents 
(and insulin not used to stabilize) 
  E11213 
Type 2 diabetes mellitus with established diabetic nephropathy, inadequately controlled with  diet or oral agents 
but adequately controlled with insulin 
  E11214 Type 2 diabetes mellitus with established diabetic nephropathy, inadequately controlled with   insulin 
  E11219 Type 2 diabetes mellitus with established diabetic nephropathy, level of control unspecified 
  E1122 Type 2 diabetes mellitus with end-stage renal disease [ESRD] 
  E11220 Type 2 diabetes mellitus with end-stage renal disease [ESRD], adequately controlled with diet or oral agents 
  E11221 Type 2 diabetes mellitus with end-stage renal disease [ESRD], adequately controlled with insulin 
  E11222 
Type 2 diabetes mellitus with end-stage renal disease [ESRD], inadequately controlled with diet or oral agents 
( and insulin not used to stabilize) 
  E11223 
Type 2 diabetes mellitus with end-stage renal disease [ESRD], inadequately controlled with diet or oral agents but 
adequately controlled with insulin 
  E11224 Type 2 diabetes mellitus with end-stage renal disease [ESRD], inadequately controlled with insulin 
  E11229 Type 2 diabetes mellitus with end-stage renal disease [ESRD] ,level of control unspecified 
  E1123 Type 2 diabetes mellitus with established or advanced kidney disease 
  E1128 Type 2 diabetes mellitus with other specified kidney complication not elsewhere classified 
  E11280 Type 2 diabetes mellitus with other specified renal complication, adequately controlled with diet or oral agents 
  E11281 Type 2 diabetes mellitus with other specified renal complication, adequately controlled with insulin 
  E11282 
Type 2 diabetes mellitus with other specified renal complication, inadequately controlled with diet or oral agents 
(and insulin not used to stabilize) 
  E11283 
Type 2 diabetes mellitus with other specified renal complication, inadequately controlled with diet or oral agents 
but adequately controlled with insulin 
  E11284 Type 2 diabetes mellitus with other specified renal complication, inadequately controlled with insulin 
  E11289 Type 2 diabetes mellitus with other specified renal complication, level of control unspecified 
  E11290 Type 2 diabetes mellitus with renal complication unspecified, adequately controlled with diet or oral agents 
  E11291 Type 2 diabetes mellitus with renal complication unspecified, adequately controlled with insulin 
  E11292 
Type 2 diabetes mellitus with renal complication unspecified, inadequately controlled with diet or oral agents  
(and insulin not used to stabilize) 
  E11293 
Type 2 diabetes mellitus with renal complication unspecified, inadequately controlled with diet or oral agents but 
adequately controlled with insulin 
  E11294 Type 2 diabetes mellitus with renal complication unspecified, inadequately controlled with insulin 
  E11299 Type 2 diabetes mellitus with renal complication unspecified, level of control unspecified 
  E1320 Other specified diabetes mellitus with incipient diabetic nephropathy 
  E13200 
Other specified diabetes mellitus with incipient diabetic nephropathy, adequately controlled with diet or oral 
agents 
  E13201 Other specified diabetes mellitus with incipient diabetic nephropathy, adequately controlled with insulin 
  E13202 
Other specified diabetes mellitus with incipient diabetic nephropathy, inadequately controlled with diet or oral 
agents (and insulin not used to stabilize) 
  E13203 
Other specified diabetes mellitus with incipient diabetic nephropathy, inadequately controlled with diet or oral 
agents but adequately controlled with insulin 
  E13204 Other specified diabetes mellitus with incipient diabetic nephropathy, inadequately controlled with insulin 
  E13209 Other specified diabetes mellitus with incipient diabetic nephropathy, level of control unspecified 
  E1321 Other specified diabetes mellitus with established diabetic nephropathy 
  E13210 
Other specified diabetes mellitus with established diabetic nephropathy, adequately controlled with diet or oral 
agents 
  E13211 Other specified diabetes mellitus with established diabetic nephropathy, adequately controlled with insulin 
  E13212 
Other specified diabetes mellitus with established diabetic nephropathy, inadequately controlled with diet or oral 
agents (and insulin not used to stabilize) 
  E13213 
Other specified diabetes mellitus with established diabetic nephropathy, inadequately controlled with diet or oral 
agents but adequately controlled with insulin 
  E13214 Other specified diabetes mellitus with established diabetic nephropathy, inadequately controlled with insulin 
  E13219 Other specified diabetes mellitus with established diabetic nephropathy, level of control unspecified 
  E1322 Other specified diabetes mellitus with end-stage renal disease [ESRD] 
  E13220 
Other specified diabetes mellitus with end-stage renal disease [ESRD], adequately controlled with diet or oral 
agents 
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  E13221 Other specified diabetes mellitus with end-stage renal disease [ESRD], adequately controlled with insulin 
  E13222 
Other specified diabetes mellitus with end-stage renal disease [ESRD], inadequately controlled with diet or oral 
agents (and insulin not used to stabilize) 
  E13223 
Other specified diabetes mellitus with end-stage renal disease [ESRD], inadequately controlled with diet or oral 
agents but adequately controlled with insulin 
  E13224 Other specified diabetes mellitus with end-stage renal disease [ESRD], inadequately controlled with insulin 
  E13229 Other specified diabetes mellitus with end-stage renal disease [ESRD] ,level of control unspecified 
  E1323 Other specified diabetes mellitus with established or advanced kidney disease 
  E1328 Other specified diabetes mellitus with other specified kidney complication not elsewhere classified 
  E13280 
Other specified diabetes mellitus with other specified renal complication, adequately controlled with diet or oral 
agents 
  E13281 Other specified diabetes mellitus with other specified renal complication, adequately controlled wtih insulin 
  E13282 
Other specified diabetes mellitus with other specified renal complication, inadequately controlled with diet or oral 
agents (and insulin not used to stabilize) 
  E13283 
Other specified diabetes mellitus with other specified renal complication, inadequately controlled with diet or oral 
agents but adequately controlled with insulin 
  E13284 Other specified diabetes mellitus with other specified renal complication, inadequately controlled with insulin 
  E13289 Other specified diabetes mellitus with other specified renal complication, level of control unspecified 
  E13290 
Other specified diabetes mellitus with renal complication unspecified, adequately controlled with diet or oral 
agents 
  E13291 Other specified diabetes mellitus with renal complication unspecified, adequately controlled with insulin 
  E13292 
Other specified diabetes mellitus with renal complication unspecified, inadequately controlled with diet or oral 
agents (and insulin not used to stabilize) 
  E13293 
Other specified diabetes mellitus with renal complication unspecified, inadequately controlled with diet or oral 
agents but adequately controlled with insulin 
  E13294 Other specified diabetes mellitus with renal complication unspecified, inadequately controlled with insulin 
  E13299 Other specified diabetes mellitus with renal complication unspecified, level of control unspecified 
  E1420 Unspecified diabetes mellitus with incipient diabetic nephropathy 
  E14200 Unspecified diabetes mellitus with incipient diabetic nephropathy, adequately controlled with diet or oral agents 
  E14201 Unspecified diabetes mellitus with incipient diabetic nephropathy, adequately controlled with insulin 
  E14202 
Unspecified diabetes mellitus with incipient diabetic nephropathy, inadequately controlled with diet or oral agents 
(and insulin not used to stabilize) 
  E14203 
Unspecified diabetes mellitus with incipient diabetic nephropathy, inadequately controlled with diet or oral agents 
but adequately controlled with insulin 
  E14204 Unspecified diabetes mellitus with incipient diabetic nephropathy, inadequately controlled  with insulin 
  E14209 Unspecified diabetes mellitus with incipient diabetic nephropathy, level of control unspecified 
  E1421 Unspecified diabetes mellitus with established diabetic nephropathy 
  E14210 Unspecified diabetes mellitus with established diabetic nephropathy, adequately controlled with diet or oral agents 
  E14211 Unspecified diabetes mellitus with established diabetic nephropathy, adequately controlled with insulin 
  E14212 
Unspecified diabetes mellitus with established diabetic nephropathy, inadequately controlled with diet or oral 
agents (and insulin not used to stabilize) 
  E14213 
Unspecified diabetes mellitus with established diabetic nephropathy, inadequately controlled with diet or oral 
agents but adequately controlled with insulin 
  E14214 Unspecified diabetes mellitus with established diabetic nephropathy, inadequately controlled with insulin 
  E14219 Unspecified diabetes mellitus with established diabetic nephropathy, level of control unspecified 
  E1422 Unspecified diabetes mellitus with end-stage renal disease [ESRD] 
  E14220 Unspecified diabetes mellitus with end-stage renal disease [ESRD], adequately controlled with diet or oral agents 
  E14221 Unspecified diabetes mellitus with end-stage renal disease [ESRD], adequately controlled with insulin 
  E14222 
Unspecified diabetes mellitus with end-stage renal disease [ESRD], inadequately controlled with diet or oral 
agents (and insulin not used to stabilize) 
  E14223 
Unspecified diabetes mellitus with end-stage renal disease [ESRD], inadequately controlled with diet or oral 
agents but adequately controlled with insulin 
  E14224 Unspecified diabetes mellitus with end-stage renal disease [ESRD], inadequately controlled  with insulin 
  E14229 Unspecified diabetes mellitus with end-stage renal disease [ESRD], level of control unspecified 
  E1423 Unspecified diabetes mellitus with established or advanced kidney disease 
  E1428 Unspecified diabetes mellitus with other specified kidney  complication not elsewhere classified 
  E14280 
Unspecified diabetes mellitus with other specified renal complication ,adequately controlled with diet or oral 
agents 
  E14281 Unspecified diabetes mellitus with other specified renal complication ,adequately controlled with insulin 
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  E14282 
Unspecified diabetes mellitus with other specified renal complication, inadequately controlled with diet or oral 
agents (and insulin not used to stabilize) 
  E14283 
Unspecified diabetes mellitus with other specified renal complication, inadequately controlled with diet or oral 
agents but adequately controlled with insulin 
  E14284 Unspecified diabetes mellitus with other specified renal complication, inadequately controlled with insulin 
  E14289 Unspecified diabetes mellitus with other specified renal complication, level of control unspecified 
  E14290 Unspecified diabetes mellitus with renal complication unspecified, adequately controlled with diet or oral agents 
  E14291 Unspecified diabetes mellitus with renal complication unspecified, adequately controlled with insulin 
  E14292 
Unspecified diabetes mellitus with renal complication unspecified, inadequately controlled with diet or oral agents 
(and insulin not used to stabilize) 
  E14293 
Unspecified diabetes mellitus with renal complication unspecified, inadequately controlled with diet or oral agents 
but adequately controlled with insulin 
  E14294 Unspecified diabetes mellitus with renal complication unspecified, inadequately controlled  with insulin 
  E14299 Unspecified diabetes mellitus with renal complication unspecified, level of control unspecified 
  I12 Hypertensive renal disease 
  I13 Hypertensive heart and renal disease 
  N00 Acute nephritic syndrome 
  N000 Acute nephritic syndrome, minor glomerular abnormality 
  N001 Acute nephritic syndrome, focal and segmental glomerular lesions 
  N002 Acute nephritic syndrome, diffuse membranous glomerulonephritis 
  N003 Acute nephritic syndrome, diffuse mesangial proliferative glomerulonephritis 
  N004 Acute nephritic syndrome, diffuse endocapillary proliferative glomerulonephritis 
  N005 Acute nephritic syndrome, diffuse mesangiocapillary glomerulonephritis 
  N006 Acute nephritic syndrome, dense deposit disease 
  N007 Acute nephritic syndrome, diffuse crescentic glomerulonephritis 
  N008 Acute nephritic syndrome, other 
  N009 Acute nephritic syndrome, unspecified 
  N01 Rapidly progressive nephritic syndrome 
  N010 Rapidly progressive nephritic syndrome, minor glomerular abnormality 
  N011 Rapidly progressive nephritic syndrome, focal and segmental glomerular lesions 
  N012 Rapidly progressive nephritic syndrome, diffuse membranous glomerulonephritis 
  N013 Rapidly progressive nephritic syndrome, diffuse mesangial proliferative glomerulonephritis 
  N014 Rapidly progressive nephritic syndrome, diffuse endocapillary proliferative glomerulonephritis 
  N015 Rapidly progressive nephritic syndrome, diffuse mesangiocapillary glomerulonephritis 
  N016 Rapidly progressive nephritic syndrome, dense deposit disease 
  N017 Rapidly progressive nephritic syndrome, diffuse crescentic glomerulonephritis 
  N018 Rapidly progressive nephritic syndrome, other 
  N019 Rapidly progressive nephritic syndrome, unspecified 
  N02 Recurrent and persistent haematuria 
  N020 Recurrent and persistent haematuria, minor glomerular abnormality 
  N021 Recurrent and persistent haematuria, focal and segmental glomerular lesions 
  N022 Recurrent and persistent haematuria, diffuse membranous glomerulonephritis 
  N023 Recurrent and persistent haematuria, diffuse mesangial proliferative glomerulonephritis 
  N024 Recurrent and persistent haematuria, diffuse endocapillary proliferative glomerulonephritis 
  N025 Recurrent and persistent haematuria, diffuse mesangiocapillary glomerulonephritis 
  N026 Recurrent and persistent haematuria, dense deposit disease 
  N027 Recurrent and persistent haematuria, diffuse crescentic glomerulonephritis 
  N028 Recurrent and persistent haematuria, other 
  N029 Recurrent and persistent haematuria, unspecified 
  N03 Chronic nephritic syndrome 
  N030 Chronic nephritic syndrome, minor glomerular abnormality 
  N031 Chronic nephritic syndrome, focal and segmental glomerular lesions 
  N032 Chronic nephritic syndrome, diffuse membranous glomerulonephritis 
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  N033 Chronic nephritic syndrome, diffuse mesangial proliferative glomerulonephritis 
  N034 Chronic nephritic syndrome, diffuse endocapillary proliferative glomerulonephritis 
  N035 Chronic nephritic syndrome, diffuse mesangiocapillary glomerulonephritis 
  N036 Chronic nephritic syndrome, dense deposit disease 
  N037 Chronic nephritic syndrome, diffuse crescentic glomerulonephritis 
  N038 Chronic nephritic syndrome, other 
  N039 Chronic nephritic syndrome, unspecified 
  N04 Nephrotic syndrome 
  N040 Nephrotic syndrome, minor glomerular abnormality 
  N041 Nephrotic syndrome, focal and segmental glomerular lesions 
  N042 Nephrotic syndrome, diffuse membranous glomerulonephritis 
  N043 Nephrotic syndrome, diffuse mesangial proliferative glomerulonephritis 
  N044 Nephrotic syndrome, diffuse endocapillary proliferative glomerulonephritis 
  N045 Nephrotic syndrome, diffuse mesangiocapillary glomerulonephritis 
  N046 Nephrotic syndrome, dense deposit disease 
  N047 Nephrotic syndrome, diffuse crescentic glomerulonephritis 
  N048 Nephrotic syndrome, other 
  N049 Nephrotic syndrome, unspecified 
  N05 Unspecified nephritic syndrome 
  N050 Unspecified nephritic syndrome, minor glomerular abnormality 
  N051 Unspecified nephritic syndrome, focal and segmental glomerular lesions 
  N052 Unspecified nephritic syndrome, diffuse membranous glomerulonephritis 
  N053 Unspecified nephritic syndrome, diffuse mesangial proliferative glomerulonephritis 
  N054 Unspecified nephritic syndrome, diffuse endocapillary proliferative glomerulonephritis 
  N055 Unspecified nephritic syndrome, diffuse mesangiocapillary glomerulonephritis 
  N056 Unspecified nephritic syndrome, dense deposit disease 
  N057 Unspecified nephritic syndrome, diffuse crescentic glomerulonephritis 
  N058 Unspecified nephritic syndrome, other 
  N059 Unspecified nephritic syndrome, unspecified 
  N06 Isolated proteinuria with specified morphological lesion 
  N060 Isolated proteinuria with minor glomerular abnormality 
  N061 Isolated proteinuria with focal and segmental glomerular lesions 
  N062 Isolated proteinuria with diffuse membranous glomerulonephritis 
  N063 Isolated proteinuria with diffuse mesangial proliferative glomerulonephritis 
  N064 Isolated proteinuria with diffuse endocapillary proliferative glomerulonephritis 
  N065 Isolated proteinuria with diffuse mesangiocapillary glomerulonephritis 
  N066 Isolated proteinuria with dense deposit disease 
  N067 Isolated proteinuria with diffuse crescentic glomerulonephritis 
  N068 Isolated proteinuria with specified morphological lesion, other 
  N069 Isolated proteinuria with specified morphological lesion, unspecified 
  N07 Hereditary nephropathy, not elsewhere classified 
  N070 Hereditary nephropathy, not elsewhere classified, minor glomerular abnormality 
  N071 Hereditary nephropathy, not elsewhere classified, focal and segmental glomerular lesions 
  N072 Hereditary nephropathy, not elsewhere classified, diffuse membranous glomerulonephritis 
  N073 Hereditary nephropathy, not elsewhere classified, diffuse mesangial proliferative glomerulonephritis 
  N074 Hereditary nephropathy, not elsewhere classified, diffuse endocapillary proliferative glomerulonephritis 
  N075 Hereditary nephropathy, not elsewhere classified, diffuse mesangiocapillary glomerulonephritis 
  N076 Hereditary nephropathy, not elsewhere classified, dense deposit disease 
  N077 Hereditary nephropathy, not elsewhere classified, diffuse crescentic glomerulonephritis 
  N078 Hereditary nephropathy, not elsewhere classified, other 
  N079 Hereditary nephropathy, not elsewhere classified, unspecified 
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  N08 Glomerular disorders in diseases classified elsewhere 
  N080 Glomerular disorders in infectious and parasitic diseases classified elsewhere 
  N081 Glomerular disorders in neoplastic diseases 
  N082 Glomerular disorders in blood diseases and disorders involving the immune mechanism 
  N083 Glomerular disorders in diabetes mellitus 
  N0831 Glomerular disorders in diabetes mellitus, chronic kidney disease, stage 1 
  N0832 Glomerular disorders in diabetes mellitus, chronic kidney disease, stage 2 
  N0833 Glomerular disorders in diabetes mellitus, chronic kidney disease, stage 3 
  N0834 Glomerular disorders in diabetes mellitus, chronic kidney disease, stage 4 
  N0835 Glomerular disorders in diabetes mellitus, chronic kidney disease, stage 5 
  N0838 Other glomerular disorders in diabetes mellitus 
  N0839 Unspecified glomerular disorders in diabetes mellitus 
  N084 Glomerular disorders in other endocrine, nutritional and metabolic diseases 
  N085 Glomerular disorders in systemic connective tissue disorders 
  N088 Glomerular disorders in other diseases classified elsewhere 
  N10 Acute tubulo-interstitial nephritis 
  N11 Chronic tubulo-interstitial nephritis 
  N110 Nonobstructive reflux-associated chronic pyelonephritis 
  N111 Chronic obstructive pyelonephritis 
  N118 Other chronic tubulo-interstitial nephritis 
  N119 Chronic tubulo-interstitial nephritis, unspecified 
  N12 Tubulo-interstitial nephritis, not specified as acute or chronic 
  N13 Obstructive and reflux uropathy 
  N130 Hydronephrosis with ureteropelvic junction obstruction 
  N131 Hydronephrosis with ureteral stricture, not elsewhere classified 
  N132 Hydronephrosis with renal and ureteral calculous obstruction 
  N133 Other and unspecified hydronephrosis 
  N134 Hydroureter 
  N135 Kinking and stricture of ureter without hydronephrosis 
  N136 Pyonephrosis 
  N137 Vesicoureteral-reflux-associated uropathy 
  N138 Other obstructive and reflux uropathy 
  N139 Obstructive and reflux uropathy, unspecified 
  N14 Drug- and heavy-metal-induced tubulo-interstitial and tubular conditions 
  N140 Analgesic nephropathy 
  N141 Nephropathy induced by other drugs, medicaments and biological substances 
  N142 Nephropathy induced by unspecified drug, medicament or biological substance 
  N143 Nephropathy induced by heavy metals 
  N144 Toxic nephropathy, not elsewhere classified 
  N15 Other renal tubulo-interstitial diseases 
  N150 Balkan nephropathy 
  N151 Renal and perinephric abscess 
  N158 Other specified renal tubulo-interstitial diseases 
  N159 Renal tubulo-interstitial disease, unspecified 
  N16 Renal tubulo-interstitial disorders in diseases classified elsewhere 
  N160 Renal tubulo-interstitial disorders in infectious and parasitic diseases classified elsewhere 
  N161 Renal tubulo-interstitial disorders in neoplastic diseases 
  N162 Renal tubulo-interstitial disorders in blood diseases and disorders involving the immune mechanism 
  N163 Renal tubulo-interstitial disorders in metabolic diseases 
  N164 Renal tubulo-interstitial disorders in systemic connective tissue disorders 
  N165 Renal tubulo-interstitial disorders in transplant rejection 
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  N168 Renal tubulo-interstitial disorders in other diseases classified elsewhere 
  N17 Acute renal failure 
  N170 Acute renal failure with tubular necrosis 
  N171 Acute renal failure with acute cortical necrosis 
  N172 Acute renal failure with medullary necrosis 
  N178 Other acute renal failure 
  N179 Acute renal failure, unspecified 
  N18 Chronic renal failure 
  N180 End-stage renal disease 
  N181 Chronic kidney disease, stage 1 
  N182 Chronic kidney disease, stage 2 
  N183 Chronic kidney disease, stage 3 
  N184 Chronic kidney disease, stage 4 
  N185 Chronic kidney disease, stage 5 
  N188 Other chronic renal failure 
  N189 Chronic kidney disease, unspecified 
  N19 Unspecified kidney failure 
  N20 Calculus of kidney and ureter 
  N200 Calculus of kidney 
  N201 Calculus of ureter 
  N202 Calculus of kidney with calculus of ureter 
  N209 Urinary calculus, unspecified 
  N21 Calculus of lower urinary tract 
  N210 Calculus in bladder 
  N211 Calculus in urethra 
  N218 Other lower urinary tract calculus 
  N219 Calculus of lower urinary tract, unspecified 
  N22 Calculus of urinary tract in diseases classified elsewhere 
  N220 Urinary calculus in schistosomiasis [bilharziasis] 
  N228 Calculus of urinary tract in other diseases classified elsewhere 
  N23 Unspecified renal colic 
  
DXCODE 2504 DIAB RENAL MANIF ADULT 
  25040 DIAB RENAL MANIF ADULT 
  25041 DIAB RENAL MANIF JUVEN 
  4030 MAL HYPERTENS RENAL DIS NO RF 
  40300 MAL HYPERTENS RENAL DIS NO RF 
  40301 MAL HYPERTENS RENAL DISEASE W RF 
  4031 BEN HYPERTENS RENAL DISEASE NO RF 
  40310 BEN HYPERTENS RENAL DISEASE NO RF 
  40311 BEN HYPERTENS RENAL DISEASE W RF 
  4039 HYPERTENS RENAL DIS NOS NO RF 
  40390 HYPERTENS RENAL DIS NOS NO RF 
  40391 HYPERTENS RENAL DIS NOS W RF 
  4040 MAL HYPER HRT/REN DIS NO CHF/RF 
  40400 MAL HYPER HRT/REN DIS NO CHF/RF 
  40401 MAL HYPERTENS HRT/REN W CHF 
  40402 MAL HYPERTENS HRT/REN W RF 
  40403 MAL HYPER HRT/REN DIS W CHF/RF 
  4041 BEN HYPER HRT/REN DIS NO CHF/RF 
  40410 BEN HYPER HRT/REN DIS NO CHF/RF 
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  40411 BEN HYPERTENS HRT/REN DIS W CHF 
  40412 BEN HYPERTENS HRT/REN DIS W RF 
  40413 BEN HYPER HRT/REN DIS W CHF/RF 
  4049 HYPER HRT/REN DIS NOS NO CHF/RF 
  40490 HYPER HRT/REN DIS NOS NO CHF/RF 
  40491 HYPERTENS HRT/REN DIS NOS W CHF 
  40492 HYPERTENS HRT/REN DIS NOS W RF 
  40493 HYPER HRT/REN DIS NOS W CHF/RF 
  5830 PROLIFERAT NEPHRITIS NOS 
  5831 MEMBRANOUS NEPHRITIS NOS 
  5832 MEMBRANOPROLIF NEPHR NOS 
  5834 RAPIDLY PROG NEPHRIT NOS 
  5836 RENAL CORT NECROSIS NOS 
  5837 NEPHR NOS/MEDULL NECROS 
  5838 NEPHRITIS NOS IN OTH DIS 
  58381 NEPHRITIS NOS IN OTH DIS 
  58389 NEPHRITIS NEC 
  5839 NEPHRITIS NOS 
  5845 LOWER NEPHRON NEPHROSIS 
  5846 AC RENAL FAIL, CORT NECR 
  5847 AC REN FAIL, MEDULL NECR 
  5848 AC RENAL FAILURE NEC 
  5849 ACUTE RENAL FAILURE NOS 
  585 CHRONIC RENAL FAILURE 
  5850 CHRONIC RENAL FAILURE 
  586 RENAL FAILURE NOS 
  5860 RENAL FAILURE NOS 
  5888 IMPAIRED RENAL FUNCT NEC 
  5889 IMPAIRED RENAL FUNCT NOS 
  5920 CALCULUS OF KIDNEY 
  5921 CALCULUS OF URETER 
  5929 URINARY CALCULUS NOS 
  5939 RENAL   URETERAL DIS NOS 
  
OHIPDX 403 Hypertensive renal disease 
  585 Chronic renal failure, uremia 
Chronic kidney disease codes 
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type code description 
INCODE 1NQ87DA 
Excision partial, rectum endoscopic 
[laparoscopic, laparoscopic-assisted, hand-
assisted] approach closure by apposition 
technique [e.g. suturing, stapling] or no closure 
required (for tissue regeneration) 
  1NQ87DE 
Excision partial, rectum endoscopic 
[laparoscopic, laparoscopic-assisted, hand-
assisted] approach colorectal anastomosis 
technique 
  1NQ87DX 
Excision partial, rectum endoscopic 
[laparoscopic, laparoscopic-assisted, hand-
assisted] approach stoma formation with distal 
closure 
Laparoscopy codes 
 
type code Fee Code Description 
FEECODE X310 TREATMENT PLANNING LEVEL 1 
  X311 TREATMENT PLANNING LEVEL 2 
  X312 TREATMENT PLANNING LEVEL 3 
  X313 TREATMENT PLANNING LEVEL 4 
  X322 
THERA. RADIOL.-RADIUM-SEALED 
SOURCE-TREAT. PLANNING 
Radiation therapy codes 
 
type code Fee Code Description 
FEECODE G281 
D./T. PROC.INJ/INF-INTRAVEN-CHEMOTHERAPY-
EA.ADD.INJ.TO G381 
  G339 
Chemotherapy - Single agent intravenous chemotherapy i.e. 
doxorubicin, daunorubicin, epirubicin, mitoxintrone, cisplatin or 
bleomycin (greater than 10 units per metre square) 
  G345 
D&T MULT.AGENTS CHEMOTHER.GREATER THAN 10 UNITS 
PER MET.SQ. 
  G359 
D&T SING.AGENT CHEMOTHER.(GREATER THAN 2G/M2 OR 
1G/M2.) 
  G381 
D./T. PROC. INJECT/INFUS. INTRAVENOUS 
CHEMOTHERAPY-1ST INJ 
Chemotherapy codes 
 
type code description 
DX10CODE C20 Malignant neoplasm of rectum 
Rectal cancer code 
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Appendix D 
Appendix D. Definition of outcomes and sources of information 
 
Variable 
Data 
Sources 
Window Reporting Detail 
30-day mortality RPDB Indexdt to Indexdt + 30 days N (%) yes 
90-day mortality RPDB Indexdt to indexdt + 90 days N (%) yes 
1-year mortality RPDB Indexdt to indexdt + 365 days N (%) yes 
Re-operation DAD/SDS 
OHIP 
Indexdt +1 day to indexdt + 30 
days 
N (%) yes 
Major 
complication 
DAD/OHIP Indexdt to indexdt + 30 days N (%) yes 
Re-admission DAD ddate to ddate +30 days N (%) yes 
Hospital length of 
stay 
DAD -- Mean (SD) 
Median (IQR) 
Acute renal 
failure requiring 
hospitalization 
DAD Indexdt to Indexdt + 180 days N (%) yes 
Ventral hernia  DAD/SDS Indexdt to Indexdt + 180 days N (%) yes 
Bowel obstruction DAD/SDS Indexdt to Indexdt + 180 days N (%) yes 
Bleeding DAD/SDS Indexdt to Indexdt + 30 days N (%) yes 
Deep space 
infection 
DAD/SDS Indexdt + 30 days 
Dt reversal + 30 days 
N (%) yes 
N (%) yes 
Parastomal hernia DAD/SDS   
Enterocutaneous 
fistula 
DAD/SDS  N (%) yes 
Hospital length of 
stay 
   
Number of days 
spent in hospital 
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Appendix E 
Appendix E. Outcome codes 
type code description 
DX10CODE N17 Acute renal failure 
  N170 Acute renal failure with tubular necrosis 
  N171 Acute renal failure with acute cortical necrosis 
  N172 Acute renal failure with medullary necrosis 
  N178 Other acute renal failure 
  N179 Acute renal failure, unspecified 
  
DXCODE 5845 LOWER NEPHRON NEPHROSIS 
  5846 AC RENAL FAIL, CORT NECR 
  5847 AC REN FAIL, MEDULL NECR 
  5848 AC RENAL FAILURE NEC 
  5849 ACUTE RENAL FAILURE NOS 
Codes for acute kidney injury 
 
type code Fee Code Description 
FEECODE G093 Haemodiafiltration - Contin. Init & Acute (repeatx3) 
  G095 Slow Continuous Ultra Filtration - Initial & Acute (repeat) 
  G294 ARTERIOVENOUS SLOW CONT. ULTRAFILTRATN-INIT& ACUTE 
  G295 CONT. ARTERIOVENOUS HAEMOFILTRAT'N - INIT. & AC. (MAX 3) 
  G323 D./T. PROC.-DIALYSIS-HAEMODIALYSIS-ACUTE,REPEAT 
  G330 D./T. PROC.-DIALYSIS-PERITONEAL-ACUTE (UP TO 48 HRS) 
  G331 D./T. PROC.-DIALYSIS-PERITONEAL-REPEAT ACUTE (UP TO 48 HRS) 
  G866 INTERMITTENT HEMODIAL AUX TREAT CTRE(PER TREAT) 
  R849 D./T. PROC.-DIALYSIS-HEMO-INITIAL AND ACUTE 
Codes for dialysis 
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type code Fee Code Description 
FEECODE Z569 ABDOMEN PERIT/OMEN-I&D.PELVIS ABSC. RECTAL VAGINAL APPROACH 
  Z594 PERCUT.ABD.ABSCESS DRAINAGE INC.DAILY SUPERV'N 
  Z595 ABDOMEN/PERIT/OMEN.REPLACE DRAIN CATHETER IN ABDO.ABSCESS 
  
INCODE 1OT52DA Drainage, abdominal cavity using endoscopic (laparoscopic) approach 
  1OT52DATS Drainage, abdominal cavity using endoscopic (laparoscopic) approach and leaving drainage tube in situ 
  1OT52HA Drainage, abdominal cavity using percutaneous (needle) approach 
  1OT52HATS Drainage, abdominal cavity using percutaneous (needle) approach and leaving drainage tube in situ 
  1OT52HHD1 
Drainage, abdominal cavity using percutaneous transcatheter approach and anti infective irrigating 
solution 
  1OT52HHD2 Drainage, abdominal cavity using percutaneous transcatheter approach and salt irrigating solution 
  1OT52HHD3 Drainage, abdominal cavity using percutaneous transcatheter approach and other irrigating solution 
  1OT52LA Drainage, abdominal cavity using open approach 
  1OT52LATS Drainage, abdominal cavity using open (incisional) approach and leaving drainage tube in situ 
  1OT52MFQJ 
Drainage, abdominal cavity using open approach with shunt terminating in circulatory system and pump 
NEC 
  1OT52MFSJ 
Drainage, abdominal cavity using open approach with shunt terminating in circulatory system [e.g. 
LeVeen Shunt, Denver Shunt] 
Codes for percutaneous drainage 
 
type code description 
DX10CODE T813 Disruption of operation wound, not elsewhere classified 
  T814 Infection following a procedure, not elsewhere classified 
  T8183   
  
INCODE 1OT52CQ 
Drainage, abdominal cavity using per orifice [transvaginal] needle aspiration 
technique 
  1OT52DA Drainage, abdominal cavity using endoscopic (laparoscopic) approach 
  1OT52DATS 
Drainage, abdominal cavity using endoscopic (laparoscopic) approach and leaving 
drainage tube in situ 
  1OT52HA Drainage, abdominal cavity using percutaneous (needle) approach 
  1OT52HATS 
Drainage, abdominal cavity using percutaneous (needle) approach and leaving 
drainage tube in situ 
  1OT52HHD1 
Drainage, abdominal cavity using percutaneous transcatheter approach and anti 
infective irrigating solution 
  1OT52HHD2 
Drainage, abdominal cavity using percutaneous transcatheter approach and salt 
irrigating solution 
  1OT52HHD3 
Drainage, abdominal cavity using percutaneous transcatheter approach and other 
irrigating solution 
  1OT52LA Drainage, abdominal cavity using open approach 
  1OT52LATS 
Drainage, abdominal cavity using open (incisional) approach and leaving drainage 
tube in situ 
  1OT52MFQJ 
Drainage, abdominal cavity using open approach with shunt terminating in circulatory 
system and pump NEC 
  1OT52MFSJ 
Drainage, abdominal cavity using open approach with shunt terminating in circulatory 
system [e.g. LeVeen Shunt, Denver Shunt] 
Codes for deep space infection 
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type code description 
DX10CODE K433 Parastomal hernia with obstruction, without gangrene 
  K434 Parastomal hernia with gangrene 
  K435 Parastomal hernia without obstruction or gangrene 
Codes for parastomal hernia 
 
type code Fee Code Description 
DX10CODE A410 Sepsis due to Staphylococcus aureus 
  A411 Sepsis due to other specified staphylococcus 
  A412 Sepsis due to unspecified staphylococcus 
  A413 Sepsis due to Haemophilus influenzae 
  A414 Sepsis due to anaerobes 
  A4150 Sepsis due to Escherichia coli [E.coli] 
  A4151 Sepsis due to Pseudomonas 
  A4152 Sepsis due to Serratia 
  A4158 Sepsis due to other Gram-negative organisms 
  A4159 Gram-negative septicaemia, unspecified 
  A4180 Sepsis due to Enterococcus 
  A4188 Other specified sepsis 
  A419 Sepsis, unspecified 
  G450 Vertebro-basilar artery syndrome 
  G451 Carotid artery syndrome (hemispheric) 
  G452 Multiple and bilateral precerebral artery syndromes 
  G453 Amaurosis fugax 
  G454 Transient global amnesia 
  G458 Other transient cerebral ischaemic attacks and related syndromes 
  G459 Transient cerebral ischaemic attack, unspecified 
  H341 Central retinal artery occlusion 
  I210 Acute transmural myocardial infarction of anterior wall 
  I211 Acute transmural myocardial infarction of inferior wall 
  I212 Acute transmural myocardial infarction of other sites 
  I213 Acute transmural myocardial infarction of unspecified site 
  I214 Acute subendocardial myocardial infarction 
  I2140 Acute subendocardial myocardial infarction of anterior wall 
  I2141 Acute subendocardial myocardial infarction of inferior wall 
  I2142 Acute subendocardial myocardial infarction of other sites 
  I2149 Acute subendocardial myocardial infarction, unspecified site 
  I219 Acute myocardial infarction, unspecified 
  I220 Subsequent myocardial infarction of anterior wall 
  I221 Subsequent myocardial infarction of inferior wall 
  I228 Subsequent myocardial infarction of other sites 
  I229 Subsequent myocardial infarction of unspecified site 
  I230 
Haemopericardium as current complication following acute myocardial 
infarction 
  I231 
Atrial septal defect as current complication following acute myocardial 
infarction 
  I232 
Ventricular septal defect as current complication following acute 
myocardial infarction 
  I233 
Rupture of cardiac wall without haemopericardium as current 
complication following acute myocardial infarction 
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  I234 
Rupture of chordae tendineae as current complication following acute 
myocardial infarction 
  I235 
Rupture of papillary muscle as current complication following acute 
myocardial infarction 
  I236 
Thrombosis of atrium, auricular appendage, and ventricle as current 
complications following acute myocardial infarction 
  I2380 
Papillary muscle dysfunction as current complication following acute 
myocardial infarction 
  I2381 Pericarditis as current complication following acute myocardial infarction 
  I2382 
Postmyocardial infarction angina as current complication following acute 
myocardial infarction 
  I2388 Other current complications following acute myocardial infarction 
  I2389 Current complications following acute myocardial infarction, unspecified 
  I26 Pulmonary embolism 
  I260 Pulmonary embolism with mention of acute cor pulmonale 
  I269 Pulmonary embolism without mention of acute cor pulmonale 
  I460 Cardiac arrest with successful resuscitation 
  I461 Sudden cardiac death, so described 
  I469 Cardiac arrest, unspecified 
  I4800 Paroxysmal atrial fibrillation 
  I4801 Persistent atrial fibrillation 
  I481 Atrial flutter 
  I483 Typical atrial flutter 
  I484 Atypical atrial flutter 
  I4890 Atrial fibrillation, unspecified 
  I4891 Atrial flutter, unspecified 
  I600 Subarachnoid haemorrhage from carotid siphon and bifurcation 
  I601 Subarachnoid haemorrhage from middle cerebral artery 
  I602 Subarachnoid haemorrhage from anterior communicating artery 
  I603 Subarachnoid haemorrhage from posterior communicating artery 
  I604 Subarachnoid haemorrhage from basilar artery 
  I605 Subarachnoid haemorrhage from vertebral artery 
  I606 Subarachnoid haemorrhage from other intracranial arteries 
  I607 Subarachnoid haemorrhage from intracranial artery, unspecified 
  I608 Other subarachnoid haemorrhage 
  I609 Subarachnoid haemorrhage, unspecified 
  I610 Intracerebral haemorrhage in hemisphere, subcortical 
  I611 Intracerebral haemorrhage in hemisphere, cortical 
  I612 Intracerebral haemorrhage in hemisphere, unspecified 
  I613 Intracerebral haemorrhage in brain stem 
  I614 Intracerebral haemorrhage in cerebellum 
  I615 Intracerebral haemorrhage, intraventricular 
  I616 Intracerebral haemorrhage, multiple localized 
  I618 Other intracerebral haemorrhage 
  I619 Intracerebral haemorrhage, unspecified 
  I630 Cerebral infarction due to thrombosis of precerebral arteries 
  I631 Cerebral infarction due to embolism of precerebral arteries 
  I632 
Cerebral infarction due to unspecified occlusion or stenosis of precerebral 
arteries 
  I633 Cerebral infarction due to thrombosis of cerebral arteries 
  I634 Cerebral infarction due to embolism of cerebral arteries 
  I635 
Cerebral infarction due to unspecified occlusion or stenosis of cerebral 
arteries 
  I636 Cerebral infarction due to cerebral venous thrombosis, nonpyogenic 
  I638 Other cerebral infarction 
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  I639 Cerebral infarction, unspecified 
  I64 Stroke, not specified as haemorrhage or infarction 
  I801 Phlebitis and thrombophlebitis of femoral vein 
  I802 Phlebitis and thrombophlebitis of other deep vessels of lower extremities 
  I803 Phlebitis and thrombophlebitis of lower extremities, unspecified 
  I822 Embolism and thrombosis of vena cava 
  I828 Embolism and thrombosis of other specified veins 
  J120 Adenoviral pneumonia 
  J121 Respiratory syncytial virus pneumonia 
  J122 Parainfluenza virus pneumonia 
  J123 Human metapneumovirus pneumonia 
  J128 Other viral pneumonia 
  J129 Viral pneumonia, unspecified 
  J13 Pneumonia due to Streptococcus pneumoniae 
  J14 Pneumonia due to Haemophilus influenzae 
  J150 Pneumonia due to Klebsiella pneumoniae 
  J151 Pneumonia due to Pseudomonas 
  J152 Pneumonia due to Staphylococcus 
  J153 Pneumonia due to Streptococcus, group B 
  J154 Pneumonia due to other streptococci 
  J155 Pneumonia due to Escherichia coli 
  J156 Pneumonia due to other aerobic Gram-negative bacteria 
  J157 Pneumonia due to Mycoplasma pneumoniae 
  J158 Other bacterial pneumonia 
  J159 Bacterial pneumonia, unspecified 
  J160 Chlamydial pneumonia 
  J168 Pneumonia due to other specified infectious organisms 
  J170 Pneumonia in bacterial diseases classified elsewhere 
  J171 Pneumonia in viral diseases classified elsewhere 
  J172 Pneumonia in mycoses 
  J173 Pneumonia in parasitic diseases 
  J178 Pneumonia in other diseases classified elsewhere 
  J180 Bronchopneumonia, unspecified 
  J181 Lobar pneumonia, unspecified 
  J182 Hypostatic pneumonia, unspecified 
  J188 Other pneumonia, organism unspecified 
  J189 Pneumonia, unspecified 
  J690 Pneumonitis due to food and vomit 
  J691 Pneumonitis due to oils and essences 
  J698 Pneumonitis due to other solids and liquids 
  N170 Acute renal failure with tubular necrosis 
  N171 Acute renal failure with acute cortical necrosis 
  N172 Acute renal failure with medullary necrosis 
  N178 Other acute renal failure 
  N179 Acute renal failure, unspecified 
  O87102 
Deep phlebothrombosis in the puerperium, delivered, with mention of 
postpartum complication 
  O87104 
Deep phlebothrombosis in the puerperium, postpartum condition or 
complication 
  O87109 
Deep phlebothrombosis in the puerperium, unspecified as to episode of 
care, or not applicable 
  O87802 
Other venous complications in the puerperium, delivered, with mention of 
postpartum complication 
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  O87804 
Other venous complications in the puerperium, postpartum condition or 
complication 
  O87809 
Other venous complications in the puerperium, unspecified as to episode 
of care, or not applicable 
  O87902 
Venous complication in the puerperium, unspecified, delivered, with 
mention of postpartum complication 
  O87904 
Venous complication in the puerperium, unspecified, postpartum 
condition or complication 
  O87909 
Venous complication in the puerperium, unspecified, unspecified as to 
episode of care, or not applicable 
  O88201 
Obstetric blood-clot embolism, delivered, with or without mention of 
antepartum condition 
  O88202 
Obstetric blood-clot embolism, delivered, with mention of postpartum 
complication 
  O88203 Obstetric blood-clot embolism, antepartum condition or complication 
  O88204 Obstetric blood-clot embolism, postpartum condition or complication 
  O88209 
Obstetric blood-clot embolism, unspecified as to episode of care, or not 
applicable 
  R092 Respiratory arrest 
  R4020 Persistent vegetative state 
  R4029 Coma, unspecified 
  R570 Cardiogenic shock 
  R571 Hypovolaemic shock 
  R572 Septic shock 
  R578 Other shock 
  R579 Shock, unspecified 
  R58 Haemorrhage, not elsewhere classified 
  T810 
Haemorrhage and haematoma complicating a procedure, not elsewhere 
classified 
  
FEECODE G082 
CONT. VENOVENOUS HAEMODIAFILTRAT'N - INIT. & AC. (MAX 
3) 
  G083 CONT. VENOVENOUS HAEMODIALYSIS - INIT. & AC. (MAX 3) 
  G085 CONT. VENOVENOUS HAEMOFILTRAT'N - INIT. & AC. (MAX 3) 
  G090 
VENOVENOUS SLOW CONT. ULTRAFILTRAT'N-INIT.& AC. (MAX 
3) 
  G093 Haemodiafiltration - Contin. Init & Acute (repeatx3) 
  G095 Slow Continuous Ultra Filtration - Initial & Acute (repeat) 
  G323 D./T. PROC.-DIALYSIS-HAEMODIALYSIS-ACUTE,REPEAT 
  G391 D./T. PROC-OTHER RESUSCITATION-AFT 1ST 1/4HR.(PER 1/4HR). 
  G395 D./T. PROC-OTHER RESUSCITATION-1ST 1/4HR. PER PHYS. 
  G405 
CRIT.CARE VENTIL.SUPPORT-INTENS.CARE-PHYS.IN CHGE-1ST 
DAY 
  G406 
CRIT.CARE VENT.SUPPORT INTENS.CARE PHYS IN CHGE 2ND 
TO 10DAY 
  G521 
D./T. PROC-LIFE THREAT.EMERG.SIT.-RESUSCITATION-1ST 
1/4HR. 
  G522 
D/T PROC LIFE THREAT EMERG.SIT.RESUS.1/4HR AFT.1ST1/2 
HR. 
  G523 D./T.PROC.LIFE THREAT EMERG.SIT/RESUSC'N SECOND 1/4HR 
  G557 
D/T PROC.COMPREHEN.INTENS.CRIT.VENT.SUP.PHYS.IN CHGE-
1STDAY 
  G558 
D/T PROC.COMP.INTENS.CRIT.VENT.PHYS.IN CHGE 
2NDTO10THDAY 
  G860 HOSPITAL HEMODIALYSIS 
  G861 HOSPITAL PERITONEAL DIALYSIS 
  G862 HOSPITAL SELF CARE OR SATELLITE HEMODIALYSIS 
  G863 INDEPENDENT HEALTH CARE FACILITY HEMODIALYSIS 
  G864 HOME PERITONEAL DIALYSIS 
  G865 HOME HEMODIALYSIS 
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  G866 INTERMITTENT HEMODIAL AUX TREAT CTRE(PER TREAT) 
  R849 D./T. PROC.-DIALYSIS-HEMO-INITIAL AND ACUTE 
  
INCODE 1LZ19HHU1A 
Transfusion, circulatory system NEC using autologous transfusion of red 
cell concentrates 
  1LZ19HHU1J 
Transfusion, circulatory system NEC using homologous transfusion of red 
cell concentrates 
  1LZ19HHU2A 
Transfusion, circulatory system NEC using autologous transfusion of 
plasma (fresh, frozen, stored) 
  1LZ19HHU2J 
Transfusion, circulatory system NEC using homologous transfusion of 
plasma (fresh, frozen, stored) 
  1LZ19HHU4J 
Transfusion, circulatory system NEC using homologous transfusion of 
platelets 
  1LZ19HHU5J 
Transfusion, circulatory system NEC using homologous transfusion of 
cryoprecipitate 
  1LZ19HHU9A 
Transfusion, circulatory system NEC using autologous transfusion of 
whole blood 
  1LZ19HHU9J 
Transfusion, circulatory system NEC using homologous transfusion of 
whole blood 
  3GT20WC Computerized tomography [CT], lung NEC with enhancement (contrast) 
  3GT20WE 
Computerized tomography [CT], lung NEC with and without 
enhancement (contrast) 
  3GT70CA Diagnostic nuclear (imaging) study, lung NEC using scintigraphy 
  3GT70CC 
Diagnostic nuclear (imaging) study, lung NEC using SPEC tomography 
(SPECT) 
  3GT70CE 
Diagnostic nuclear (imaging) study, lung NEC using PE tomography 
(PET) 
  3GT70KC 
Diagnostic nuclear (imaging) study, lung NEC using scintigraphy for 
perfusion study 
  3GT70KD 
Diagnostic nuclear (imaging) study, lung NEC using scintigraphy for 
ventilation study 
  3GT70KE 
Diagnostic nuclear (imaging) study, lung NEC using scintigraphy for 
perfusion and ventilation study 
  3IM10VC 
Xray, pulmonary artery following intravenous injection of contrast (with 
or without fluoroscopy) 
  3IM10VX 
Xray, pulmonary artery following intraarterial injection of contrast (with 
or without fluoroscopy) 
  3IM10VY 
Xray, pulmonary artery following intracardiac injection of contrast (with 
or without fluoroscopy) 
  3IM12VA Fluoroscopy, pulmonary artery without contrast 
  3JY10VA Xray, thoracic vessels NEC without contrast (with or without fluoroscopy 
  3JY10VC 
Xray, thoracic vessels NEC following intravenous injection of contrast 
(with or without fluoroscopy) 
  3JY10VN Xray, thoracic vessels NEC with fluoroscopy 
  3JY10VX 
Xray, thoracic vessels NEC following intraarterial injection of contrast 
(with or without fluoroscopy) 
  3JY12VA Fluoroscopy, thoracic vessels NEC without contrast 
  3JY20WC 
Computerized tomography, thoracic vessels NEC with enhancement 
(contrast) 
  3JY20WE 
Computerized tomography, thoracic vessels NEC with and without 
enhancement (contrast) 
  3KR10VA Xray, veins of leg NEC without contrast (with or without fluoroscopy) 
  3KR10VC 
Xray, veins of leg NEC following intravenous injection of contrast (with 
or without fluoroscopy) 
  3KR10VN Xray, veins of leg NEC with fluoroscopy 
  3KR12VA Fluoroscopy, veins of leg NEC without contrast 
  3KX10VA Xray, vein NEC without contrast (with or without fluoroscopy) 
  3KX10VC 
Xray, vein NEC following intravenous injection of contrast (with or 
without fluoroscopy) 
  3KX10VN Xray, vein NEC with fluoroscopy 
  3KX10VX Xray, vein NEC following intraarterial injection of contrast 
  3KX12VA Fluoroscopy, vein NEC without contrast 
  3KX30DA Ultrasound, vein NEC alone 
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  3KX30DB Ultrasound, vein NEC with color flow 
  3KX30DC Ultrasound, vein NEC with Doppler 
  3KX30DD Ultrasound, vein NEC with color flow and Doppler 
Codes for major complications 
 
type code description 
DX10CODE K433 Parastomal hernia with obstruction, without gangrene 
  K9145 Enterostomy malfunction, not elsewhere classified 
  
INCODE 1NK52CA 
Drainage, small intestine per orifice approach aspiration [or suction] 
technique 
  1NK52CATS 
Drainage, small intestine per orifice approach leaving 
drainage/decompression tube in situ 
Codes for obstruction 
 
type code Fee Code Description 
FEECODE R764 ARTERIES-EXPLORATION OF MAJOR ARTERY 
  R905 LYMPHATIC-SPLEEN-EXC. SPLENECTOMY 
  S149 INTESTINE-INC.-ENTEROTOMY-ILEOSTOMY 
  S155 
INTESTINE-INC-ENTEROTOMY-COLONOSCOPY WITH 
LAPAROTOMY. 
  S157 INTESTINE-INC-ENTEROTOMY-COLOSTOMY. 
  S158 INTESTINE-INC-ENTEROTOMY-CAECOSTOMY. 
  S160 INTESTINE-INC-ENTEROTOMY-ENTERO-ENTEROSTOMY. 
  S162 INTESTINE-EXC.-LOC.LESION OF INTESTINE. 
  S165 INTESTINE-EXC-ANASTOMOSIS-SMALL INTESTINE-OTHER. 
  S166 
INTESTINE-EXC.-SML+LGE INTESTINE-TERM.ILEUM-CAECUM 
ASC.COLON 
  S167 INTESTINE-EXC.-ANASTO.-LARGE INTESTINE -ANY PORTION. 
  S168 INTESTINE-EXC.-ILEOSTOMY.SUBTOTAL COLECTOMY 
  S169 
INTESTINE-EXC-TOTAL COLECTOMY W/ILEO-RECTAL 
ANASTOMOSIS. 
  S171 
INTESTINE-EXC-LT.HEMICOLECTOMY WITH ANT.RESECT/ANAST. 
ETC. 
  S173 INTESTINE-EXC.-ILEOSTOMY-2-SURGEON TEAM-ABDOMINAL 
  S175 INTESTINE-OBSTRUCTION- NO RESECTION ONE STAGE 
  S176 INTESTINE-OBSTRUCTION-+-ENTERO/ENTEROSTOMY ONE STAGE 
  S177 INTESTINAL-OBSTRUCTION-ONE STAGE-WITH RESECTION 
  S180 INTESTINE-OBSTRUCTION-WITH ENTEROTOMY. 
  S181 INTESTINE-REP.-REVISION-ILEOSTOMY/COLOSTOMY-SKIN LEVEL. 
  S182 
INTESTINE-REP.-REVISION-ILEOSTOMY/COLOSTOMY-FULL 
THICKNESS. 
  S184 INTESTINE-SUTURE OF INTESTINE 
  S188 INTESTINE-EXC.-BOWEL RESECTION-WITHOUT ANASTOMOSIS. 
  S213 
RECTUM-EXC.-PROCTECTOMY-ANTERIOR 
RESECT./PROCTOSIGMOIDECTOMY 
  S214 
RECTUM-EXC.-PROCTECTOMY-ABDOMINO-PERINEAL RESEC/PULL 
THRU 
  S215 
RECTUM-EXC.PROCTECTOMY-2 SURG. TEAM ABDOMINAL 
SURGEON 
  S216 RECTUM-EXC.-PROCTECTOMY-2 SURG. TEAM PERINEAL SURGEON 
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  S217 RECTUM-EXC.-PROCTECTOMY-HARTMANN PROC. 
  S223 RECTUM-REPAIR-ANASTOMOSIS OF RECTUM 
  S229 RECTUM-SUTURE-RECTUM,TRAUMA-EXTERNAL APPROACH. 
  S231 RECTUM-SUTURE-CLOSURE OF FISTULA-RECTO VAGINAL 
  S271 LIVER-EXCISION-EXTENDED RIGHT LOBECTOMY 
  S312 ABDOMEN-INC-LAPAROTOMY WITH/WITHOUT BIOPSY 
  S313 ABDOMEN-INC-PERITONEAL ABSCESS-SUBPHRENIC. 
  S314 ABDOMEN-INC-PERITONEAL ABSCESS-ABDOMINAL. 
  S340 ABDOMEN-REP-HERNIA-VENTRAL POST-OP. 
  S343 ABDOMEN-SUTURE-SECONDARY CLOSURE FOR EVISCERATION 
  S344 ABDOMEN-REPAIR-HERNIA-MASSIVE INCISIONAL 
  
INCODE 1NM80LA 
Repair, large intestine open approach using apposition technique [e.g. suturing, 
stapling] 
  1NM80LAFH Repair, large intestine open approach using biodegradable binding ring 
  1NM80LAW2 Repair, large intestine open approach using collagen powder 
  1NM80LAW3 Repair, large intestine open approach using fibrin glue 
  1NM80LAXXE 
Repair, large intestine open approach using local transposition flap [e.g. 
omental patch] 
  1NQ87TF 
Excision partial, rectum open abdominal approach [e.g. anterior] stoma 
formation with distal closure 
  1OT35LAM0 
Pharmacotherapy (local), abdominal cavity using open approach and 
antineoplastic agent 
  2OT70LA Inspection, abdominal cavity using open approach 
Codes for re-operation 
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